1018-00009 · Client 1018 · Strategy

tcja-impact-analysis-memo.docx DOCUMENT M&A / Corporate

168 / 176 ← → ✕

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

MEMORANDUM

TO: Leonard Cross, Responsible Partner, Tax Department Garrett Simmons, Lead Associate, Tax Department

FROM: Leila Nazari, Working Associate, Tax Department

DATE: August 25, 2022

RE: Impact of the Tax Cuts and Jobs Act on Penterra Pharmaceuticals Corp.'s Transfer Pricing Positions — Tax Years 2017 vs. 2018–2020

MATTER NO.: 1018-00009

CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)

Right-click to update Table of Contents

I. Executive Summary

This memorandum analyzes the impact of the Tax Cuts and Jobs Act ("TCJA"), Pub. L. No. 115-97, 131 Stat. 2054 (2017), effective January 1, 2018, on the transfer pricing positions of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") that are currently under examination by the Internal Revenue Service (IRS Exam Team ID: LB&I-NE-TP-2022-00641, covering tax years 2017 through 2020). The purpose of this memorandum is to provide a comprehensive legal analysis of the TCJA's operative provisions as they bear on PPC's transfer pricing exposure, to quantify the differential impact of IRS proposed adjustments across the pre-TCJA and post-TCJA periods, and to identify the strategic implications for PPC's defense posture.

The TCJA fundamentally altered the U.S. international tax landscape through several provisions of direct relevance to PPC's examination:

(a) the reduction of the federal corporate income tax rate from 35% to 21%, effective for tax years beginning after December 31, 2017, under IRC § 11(b) as amended;

(b) the enactment of the Global Intangible Low-Taxed Income ("GILTI") regime under IRC § 951A, which requires U.S. shareholders of controlled foreign corporations ("CFCs") to include currently in gross income the CFC's income in excess of a deemed return on tangible assets, thereby ending indefinite deferral of CFC intangible income;

(c) the introduction of the Base Erosion and Anti-Abuse Tax ("BEAT") under IRC § 59A, which imposes a minimum tax on U.S. corporations making deductible payments to related foreign persons; and

(d) modifications to the treatment of foreign-derived intangible income ("FDII") under IRC § 250, which provides a preferential effective rate of 13.125% for qualifying domestic income attributable to foreign markets.

These changes create a materially different exposure profile for TY 2017 (the last pre-TCJA year, subject to the 35% corporate rate and the traditional deferral regime) versus TY 2018–2020 (the post-TCJA period, subject to the 21% corporate rate and the new anti-base-erosion provisions). The differential affects both the quantum of any IRC § 482 adjustments on a tax-dollar basis and the interaction of such adjustments with the GILTI, BEAT, and FDII regimes.

The IRS has communicated proposed net adjustments totaling approximately $380.4 million across all four examination years. These proposed adjustments relate to PPC's cost-sharing arrangement ("CSA") with its Irish subsidiary, Penterra Biopharma International DAC ("PBI"), and to the royalty rate under a separate legacy IP license between PPC and PBI. The TCJA's rate reduction from 35% to 21% means that the per-dollar federal income tax impact of adjustments for TY 2018–2020 is approximately 40% lower than for TY 2017. However, the GILTI regime may partially offset this benefit by imposing additional U.S. tax on PBI's income that was previously subject to indefinite deferral — although, critically, this GILTI effect also operates in reverse, such that any IRC § 482 adjustment that reduces PBI's tested income simultaneously reduces PPC's GILTI inclusion, creating a partial offset to the adjustment's tax cost.

The BEAT regime, while potentially applicable to PPC given its gross receipts, does not appear to create material additional exposure in this examination because the core intercompany payment flows at issue (cost-sharing payments and royalties) are inbound to the United States — that is, they flow from PBI to PPC — rather than constituting outbound base erosion payments from PPC to a related foreign person.

Key Conclusion: The TCJA rate reduction substantially reduces PPC's aggregate transfer pricing exposure on a tax-dollar basis for TY 2018–2020, but introduces new analytical complexities — principally the GILTI inclusion offset and the need to confirm BEAT non-applicability — that must be addressed in the defense strategy. On a per-dollar-of-adjustment basis, TY 2017 exposure is approximately 70% to 125% more costly than TY 2018–2020 exposure, depending on the applicable Irish effective tax rate for PBI's income. This differential should inform the allocation of defense resources and the structure of any settlement.

II. Scope and Purpose

This memorandum is intended to serve the following purposes:

First, it analyzes the TCJA's impact across three critical dimensions of PPC's transfer pricing positions: (1) the statutory rate change from 35% to 21% and its effect on the dollar-exposure calculations associated with the IRS's proposed IRC § 482 adjustments; (2) the interaction between proposed IRC § 482 adjustments and the GILTI regime under IRC § 951A, including the mechanics by which a § 482 adjustment that reallocates income from PBI to PPC simultaneously reduces PPC's GILTI inclusion; and (3) the interaction between the proposed adjustments and the BEAT under IRC § 59A, including an assessment of whether the direction and character of the intercompany payment flows at issue could trigger BEAT liability.

Second, this memorandum is intended to inform the broader defense strategy being coordinated by Leonard Cross and Sylvia Hartwell of this firm, and the economic analyses being prepared by Whitmore Valuation Group LLC ("Whitmore") under the Kovel arrangement established pursuant to the engagement letter dated May 10, 2022 (Reference: 1018-00009-KV). Dr. Helena Vasquez serves as the lead economist for the Whitmore engagement. The economic analyses being prepared by Whitmore, including the comparability analysis and statistical benchmarking of arm's-length ranges for the CSA cost-sharing ratios and the legacy IP royalty rate, should incorporate the rate-differential and GILTI-offset considerations identified in this memorandum when computing the tax-dollar implications of various adjustment scenarios.

Third, this memorandum provides contextual background on PPC's corporate structure and the IRS's proposed adjustments for purposes of identifying the TCJA-related issues that bear on the defense. The following contextual facts inform the analysis:

PPC is a Delaware corporation headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. The Company's common stock is traded on the Nasdaq Stock Market under the ticker symbol PPCA. For its fiscal year ended December 31, 2020, PPC reported consolidated revenue of $6.82 billion and pre-tax income of $1.47 billion. PPC is a multinational pharmaceutical company with operations in the United States and, through its subsidiaries, in over 70 countries worldwide. Its core therapeutic areas include oncology, immunology, and rare diseases.

PPC's principal foreign subsidiary for purposes of this examination is Penterra Biopharma International DAC ("PBI"), a Designated Activity Company organized under the laws of Ireland. PBI is held through Penterra Holdings Luxembourg S.à r.l. ("PHL"), a Luxembourg entity registered with the Registre de Commerce et des Sociétés under Number B 168452. PHL is treated as a disregarded entity for U.S. federal income tax purposes pursuant to Treas. Reg. § 301.7701-3, and accordingly, PPC is treated as the direct U.S. shareholder of PBI for purposes of the Subpart F and GILTI provisions. This ownership structure and its implications for CFC status are discussed further in Section V.B below.

This memorandum does not address the merits of PPC's transfer pricing positions on a stand-alone basis (i.e., whether PPC's CSA cost-sharing ratios and legacy IP royalty rate satisfy the arm's-length standard under IRC § 482 and the regulations thereunder). Those issues are the subject of the preliminary assessment memorandum dated June 15, 2022, and the defense strategy memorandum dated July 12, 2022, and are being analyzed in detail in the economic reports under preparation by Whitmore. This memorandum focuses exclusively on the TCJA's impact on the tax-dollar consequences of the IRS's proposed adjustments and the strategic implications thereof.

III. Background: PPC's IP Structure and the IRS's Proposed Adjustments

A. The Cost-Sharing Arrangement and Royalty Structure

PBI was incorporated on March 15, 2012, under the laws of Ireland as a Designated Activity Company. On July 1, 2012, PPC and PBI entered into a qualified cost-sharing arrangement (the "CSA") within the meaning of Treas. Reg. § 1.482-7. The CSA governs the development and exploitation of PPC's pharmaceutical intellectual property outside the Americas territory.

Platform Contribution Transaction. In connection with the formation of the CSA, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC on July 1, 2012. This PCT payment represented compensation for PBI's buy-in to PPC's pre-existing intellectual property, which at the time consisted of a portfolio of clinical-stage and approved oncology compounds. The PCT payment was valued based on a discounted cash flow analysis prepared by PPC's then-transfer pricing advisors, which projected the future revenue streams attributable to the pre-existing IP in the non-Americas territory and discounted them to present value as of the buy-in date. The adequacy of the PCT payment is a separate issue under examination and is addressed in the CSA regulatory analysis memorandum dated August 5, 2022.

Scope of the CSA. Under the CSA, PBI acquired the rights to develop and commercially exploit PPC's pharmaceutical IP in all territories outside the Americas (i.e., the "Non-Americas Territory," comprising Europe, the Middle East, Africa, and Asia-Pacific) in exchange for the initial PCT payment and ongoing cost-sharing payments proportional to reasonably anticipated benefits ("RAB"). PPC retained the rights to develop and exploit the same IP in the Americas (i.e., the United States, Canada, Mexico, and Central and South America). The CSA covers all intangible development activities ("IDAs") undertaken by either party that relate to the development of pharmaceutical products within the scope of the arrangement.

Cost-Sharing Percentages. PBI's cost-sharing percentages, reflecting its share of total intangible development costs under the CSA, increased over the examination period in line with the growth of PBI's reasonably anticipated benefits from the covered intangibles. The following table summarizes PBI's cost-sharing contributions for TY 2017–2020:

The gradual increase in PBI's cost-sharing percentage reflects the growing share of global pharmaceutical revenue attributable to the Non-Americas Territory during the examination period, driven in part by PBI's successful commercialization of PPC's key products in European and Asia-Pacific markets.

Legacy IP License. In addition to the CSA, PBI holds a separate license from PPC for pre-2012 vintage compounds — that is, pharmaceutical products that were fully approved and on the market prior to the establishment of the CSA on July 1, 2012, and that were therefore excluded from the CSA's scope. Under this legacy IP license, PBI pays PPC a royalty at a rate of 4.5% of net sales for the Non-Americas Territory. The legacy compound net sales and corresponding royalty payments for the examination period are as follows:

The decline in legacy compound net sales over the examination period reflects the natural lifecycle of older pharmaceutical products, including loss of patent exclusivity and generic competition in certain Non-Americas markets.

PBI's Functions and Economic Substance. PBI maintains significant economic substance in Ireland. As of December 31, 2020, PBI employed 185 full-time employees, up from 52 employees at the time of incorporation in 2012. PBI's offices are located at Sandyford Business Park, Dublin, Ireland, comprising approximately 18,000 square feet of leased office space. PBI's employees perform a range of functions, including regulatory affairs, medical affairs, commercial operations management, pharmacovigilance, supply chain coordination, market access, and general management.

PBI's Managing Director is Aidan Naughton, who has served in that capacity since 2014. The PBI board of directors held a total of 42 board meetings during the TY 2017–2020 examination period, with meetings occurring approximately quarterly but with additional sessions convened for significant commercial and regulatory decisions. PBI has incurred cumulative regulatory expenditures of approximately €47.2 million during the period from incorporation through the end of 2020, reflecting its active engagement with regulatory authorities across 68 country markets in the Non-Americas Territory.

PBI exercises independent pricing authority across its 68 country markets, establishing prices for PPC's pharmaceutical products based on local market conditions, reimbursement frameworks, competitive dynamics, and regulatory requirements. PBI's pricing decisions are made by its commercial operations team in Dublin, subject to oversight by the PBI board.

Key Products. The principal products generating revenue for PPC and PBI during the examination period include:

• Veritaxol (oncology): Global revenue of $3.12 billion (FY 2020), of which $1.34 billion was attributable to the Non-Americas Territory. Veritaxol is PPC's flagship oncology product, approved for the treatment of non-small cell lung cancer and certain hematological malignancies.

• Imvara (immunology): Global revenue of $1.87 billion (FY 2020), of which $0.79 billion was attributable to the Non-Americas Territory. Imvara is a biologic product approved for the treatment of moderate-to-severe rheumatoid arthritis and psoriatic arthritis.

• Cerulon (rare disease): Global revenue of $0.62 billion (FY 2020), of which $0.28 billion was attributable to the Non-Americas Territory. Cerulon is an enzyme replacement therapy for a rare lysosomal storage disorder.

Irish Tax Position. PBI has claimed benefits under Ireland's Knowledge Development box ("KDB") regime at an effective tax rate of 6.25% on qualifying intellectual property income from its fiscal year ending December 31, 2016 forward. Income not qualifying for the KDB is subject to the standard Irish corporation tax trading rate of 12.5%. The allocation of PBI's income between the KDB rate and the standard trading rate is relevant to the computation of foreign tax credits under IRC § 960 and the quantification of the GILTI offset, as discussed in Section V.C below.

B. The IRS's Proposed Adjustments

The IRS Large Business & International Division ("LB&I") examination team has proposed aggregate net adjustments totaling approximately $380.4 million across TY 2017–2020. The proposed adjustments fall into two principal categories, with a correlative offset to avoid double-counting:

CSA Cost-Sharing Ratio Adjustments. The IRS proposes to increase PBI's cost-sharing ratio under the CSA by 8 to 12 percentage points for each examination year, asserting that PBI's reasonably anticipated benefits from the covered intangibles are higher than reported on PPC's returns. The effect of this adjustment is to reallocate a greater share of intangible development costs to PBI, correspondingly increasing PPC's U.S. taxable income. The proposed CSA adjustments total $235.01 million across the four years, as follows:

Royalty Rate Adjustments. The IRS proposes to increase the royalty rate on the legacy IP license from 4.5% to 11.0% of Non-Americas net sales, asserting that PPC's 4.5% rate is below the arm's-length range for comparable licensing transactions involving pharmaceutical IP of similar value and risk profile. The proposed royalty adjustments total $188.04 million across the four years:

Correlative Offset. The IRS examination team has allowed a correlative offset of $42.65 million to avoid double-counting between the CSA cost-sharing ratio adjustments and the royalty rate adjustments, which arise from overlapping bases of income reallocation. This correlative offset reduces the net proposed adjustment from the gross total of $423.05 million ($235.01M + $188.04M) to $380.4 million.

Proposed Penalties. The IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty at the 20% rate on the underpayment attributable to the net § 482 allocation. Based on the IRS's proposed adjustments, the penalty exposure is calculated as $380.4 million × 21% × 20% = $15.98 million. The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h), which would apply if the price for any property or services is 400% or more (or 25% or less) of the correct price.

Status of Examination. A Notice of Proposed Adjustment ("NOPA") was issued on October 12, 2023. However, this memorandum was prepared in August 2022, and the proposed adjustments described herein are based on the early-stage analysis of potential IRS positions as communicated during the examination opening conference held on June 28, 2022. The figures set forth above reflect our best assessment of the likely scope and magnitude of the IRS's positions as of the date of this memorandum and may be refined as the examination progresses.

IV. The TCJA Rate Change: Impact on Transfer Pricing Exposure

A. Corporate Tax Rate Reduction

The most immediately consequential change enacted by the TCJA for purposes of PPC's transfer pricing examination is the reduction of the federal corporate income tax rate from 35% to 21%. This rate change, codified in IRC § 11(b) as amended by TCJA § 13001, applies to taxable years beginning after December 31, 2017.

For TY 2017, the applicable federal corporate tax rate is 35% for the full taxable year. PPC's fiscal year ends on December 31, and accordingly, PPC's 2017 taxable year began on January 1, 2017 — before the TCJA's effective date. The TCJA rate reduction therefore does not apply to TY 2017 under any theory, including the blended-rate provision of former IRC § 15 (which applied only to fiscal-year taxpayers whose taxable year straddled the January 1, 2018 effective date). Since PPC is a calendar-year taxpayer, no blended rate applies.

For TY 2018 through TY 2020, the applicable federal corporate tax rate is 21%. This rate applies uniformly across all three post-TCJA examination years.

The 14-percentage-point reduction in the corporate rate from 35% to 21% represents a 40% decrease in the federal tax cost of each dollar of IRC § 482 adjustment. This fundamental arithmetic drives much of the analysis that follows.

B. Dollar-Impact Analysis by Tax Year

The rate differential between TY 2017 and TY 2018–2020 has a direct and substantial impact on the federal income tax consequences of the IRS's proposed adjustments. The following analysis quantifies this impact on the assumption that the IRS's full proposed adjustments are sustained.

TY 2017. The IRS's proposed adjustments for TY 2017 consist of a CSA cost-sharing ratio adjustment of $48.73 million and a royalty rate adjustment of $52.95 million, less an allocable portion of the $42.65 million correlative offset. The net proposed adjustment for TY 2017 is approximately $59.03 million (after allocation of the correlative offset on a pro rata basis across all four years). At the 35% federal corporate rate, the federal income tax attributable to the TY 2017 adjustment would be approximately $20.66 million.

TY 2018–2020. The IRS's proposed adjustments for the three post-TCJA years total approximately $321.37 million in the aggregate (the balance of the $380.4 million total after allocation of $59.03 million to TY 2017). At the 21% federal corporate rate, the federal income tax attributable to the TY 2018–2020 adjustments would be approximately $67.49 million.

The following table illustrates the differential tax impact per dollar of IRC § 482 adjustment:

Strategic Observation. The rate differential means that any concession or adverse determination on TY 2017 carries a disproportionately high tax cost relative to the same dollar amount of concession for TY 2018–2020. Specifically, each dollar of adjustment sustained for TY 2017 produces $0.14 more in federal tax liability than the same dollar of adjustment sustained for TY 2018, 2019, or 2020. Defense resources should therefore be particularly focused on minimizing any TY 2017 adjustment, all else being equal.

However, it is important to note that the overall dollar volume of the IRS's proposed adjustments is lower for TY 2017 than for any individual post-TCJA year. The TY 2017 gross adjustment (before correlative offset) is $101.68 million ($48.73M CSA + $52.95M royalty), compared to $107.16 million for TY 2018, $107.82 million for TY 2019, and $106.39 million for TY 2020. This partially mitigates the per-dollar rate disadvantage, though the net effect still favors prioritizing the TY 2017 defense.

C. Penalty Rate Interaction

The IRC § 6662(e) substantial valuation misstatement penalty is computed as 20% of the underpayment of tax attributable to the substantial valuation misstatement. Because the penalty is calculated on the tax attributable to the adjustment (not on the adjustment itself), the TCJA rate reduction also reduces the penalty exposure per dollar of adjustment for TY 2018–2020.

• At 35% (TY 2017): The penalty per dollar of § 482 adjustment is $0.07 (i.e., $1.00 × 35% × 20% = $0.07).

• At 21% (TY 2018–2020): The penalty per dollar of § 482 adjustment is $0.042 (i.e., $1.00 × 21% × 20% = $0.042).

Thus, the penalty cost per dollar of adjustment is also 40% lower for the post-TCJA years.

As noted above, the IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h). The 40% penalty would apply if the transfer price used by PPC is 400% or more (or 25% or less) of the arm's-length price. While PPC's positions represent meaningful deviations from the IRS's proposed arm's-length prices, the magnitude of the deviations does not appear to reach the 400%/25% threshold for any individual transaction.

PPC's contemporaneous transfer pricing documentation was prepared by Crestfield & Associates LLP (transfer pricing partner: Susan Lam, CPA) and covers all four examination years. This documentation provides a basis for penalty protection under IRC § 6662(e)(3)(B), which requires that the taxpayer have maintained contemporaneous documentation establishing that the transfer pricing method selected and applied was reasonable and that the taxpayer reasonably concluded that the method provided the most reliable measure of an arm's-length result. We have reviewed the Crestfield documentation and believe it satisfies the reasonable-cause-and-good-faith standard for penalty protection purposes, subject to the caveats identified in the defense strategy memorandum dated July 12, 2022.

V. GILTI Regime (IRC § 951A) — Interaction with Transfer Pricing Adjustments

A. Overview of GILTI

The GILTI regime, enacted by TCJA § 14201 and codified at IRC § 951A, represents one of the most significant structural changes to the U.S. international tax system effected by the TCJA. GILTI is effective for taxable years of foreign corporations beginning after December 31, 2017, and for taxable years of U.S. shareholders in which or with which such taxable years of foreign corporations end. For PPC, which is a calendar-year taxpayer and the U.S. shareholder of the calendar-year CFC PBI, the GILTI regime applies beginning with TY 2018.

The GILTI regime requires each U.S. shareholder of a CFC to include in gross income, on a current basis, its pro rata share of the CFC's "GILTI inclusion amount." The GILTI inclusion amount is computed as follows:

GILTI = Excess of:

(i) the U.S. shareholder's aggregate pro rata share of the "tested income" of each CFC, over

(ii) the U.S. shareholder's "net deemed tangible income return" ("NDTIR"), which equals 10% of the shareholder's aggregate pro rata share of the "qualified business asset investment" ("QBAI") of each CFC, reduced by certain interest expense allocable to the CFC's tested income.

In practical terms, GILTI operates to tax currently the income of CFCs that exceeds a 10% deemed return on the CFC's tangible depreciable assets. For a pharmaceutical company like PBI, whose income is overwhelmingly derived from intangible assets (pharmaceutical IP) rather than tangible assets, the GILTI regime captures the vast majority of PBI's income as "tested income" in excess of the QBAI-based return.

IRC § 250(a)(1)(B) provides a deduction equal to 50% of a domestic corporation's GILTI inclusion amount (applicable for taxable years beginning after December 31, 2017 and before January 1, 2026; the deduction reduces to 37.5% for taxable years beginning after December 31, 2025). This deduction results in an effective U.S. tax rate on GILTI of 10.5% (i.e., 21% × 50% = 10.5%), before the application of foreign tax credits.

IRC § 960(d) allows a deemed-paid foreign tax credit equal to 80% of the foreign income taxes properly attributable to the tested income of the CFC that gives rise to the GILTI inclusion. This 80% haircut on deemed-paid credits (compared to the 100% credit historically available under pre-TCJA § 960 for Subpart F inclusions) is a deliberate design feature of the GILTI regime intended to ensure that some residual U.S. tax is imposed on CFC income even when that income is subject to foreign taxation.

B. PBI's Status as a CFC

PBI is a Designated Activity Company organized under the laws of Ireland, with its registered office at Sandyford Business Park, Dublin, Ireland. PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), which is in turn 100% owned by PPC. PHL, as noted in Section II above, is classified as a disregarded entity for U.S. federal income tax purposes under the check-the-box regulations of Treas. Reg. § 301.7701-3. As a consequence of PHL's disregarded status, PPC is treated for all purposes of the Internal Revenue Code as the direct owner of PBI's outstanding shares.

PBI is therefore a "controlled foreign corporation" within the meaning of IRC § 957(a), as PPC — a single United States shareholder within the meaning of IRC § 951(b) — owns 100% of the total combined voting power and 100% of the total value of PBI's outstanding stock. PPC's status as a "United States shareholder" under § 951(b) is established by its ownership of more than 10% of the total combined voting power of PBI.

PBI has significant "tested income" for GILTI purposes. For its fiscal year ended December 31, 2020, PBI reported pre-tax income of approximately €1.06 billion (approximately $1.16 billion at average 2020 EUR/USD exchange rates). PBI's QBAI — consisting of its depreciable tangible assets — is modest relative to its total income, as PBI's business model is intangible-asset-intensive and relies primarily on licensed and co-developed pharmaceutical intellectual property rather than owned manufacturing facilities or equipment. PBI's tested income therefore substantially exceeds its NDTIR (10% of QBAI), resulting in a significant GILTI inclusion for PPC in each post-TCJA year.

C. Impact of IRC § 482 Adjustments on GILTI

The interaction between IRC § 482 adjustments and the GILTI regime is a critical analytical issue for PPC's defense strategy. The mechanics of this interaction are as follows:

If the IRS increases PPC's U.S.-source income under IRC § 482 — by reallocating income from PBI to PPC through an increase in CSA cost-sharing ratios or an increase in the legacy IP royalty rate — the direct effect is to increase PPC's taxable income as reported on its U.S. federal income tax return. However, the correlative effect is to decrease PBI's income (and therefore PBI's "tested income" for GILTI purposes) by a corresponding amount, assuming that proper correlative or conforming adjustments are made to PBI's earnings and profits and tested income computations.

This creates a partial offset mechanism: the additional U.S. tax from the § 482 adjustment is partially mitigated by the reduction in the GILTI tax that PPC would otherwise have paid on PBI's excess intangible income. In essence, because the GILTI regime already imposes U.S. tax on PBI's income (albeit at a reduced effective rate), each dollar of income reallocated from PBI to PPC under § 482 does not create a full incremental $0.21 tax liability — instead, the incremental cost is $0.21 minus the GILTI tax that PPC would have paid on that same dollar had it remained with PBI.

The magnitude of this GILTI offset depends on the effective Irish tax rate applicable to PBI's income, because the Irish taxes paid by PBI on its income generate deemed-paid foreign tax credits under IRC § 960(d) that reduce the U.S. GILTI tax. The quantification is as follows:

For each $1 of IRC § 482 adjustment for TY 2018–2020:

Additional U.S. tax from the § 482 adjustment: $0.21 (at the 21% corporate rate).

Reduced GILTI inclusion (net of § 250 deduction and § 960 foreign tax credit):

The net U.S. GILTI tax on $1 of PBI income depends on the applicable Irish effective tax rate:

(i) KDB rate (6.25%): GILTI tax per $1 of PBI income = $1.00 × 10.5% (effective U.S. GILTI rate after § 250 deduction) minus ($0.0625 × 80%) (deemed-paid credit at 80% of Irish tax) = $0.105 − $0.050 = $0.055 per dollar.

(ii) Standard trading rate (12.5%): GILTI tax per $1 of PBI income = $1.00 × 10.5% minus ($0.125 × 80%) = $0.105 − $0.100 = $0.005 per dollar.

Net incremental U.S. tax from $1 of § 482 adjustment (after GILTI offset):

The GILTI offset is substantially more significant when PBI's income is taxed at the KDB rate of 6.25%, because the lower Irish tax rate produces smaller deemed-paid foreign tax credits, leaving a larger residual U.S. GILTI tax that is eliminated when the income is reallocated to PPC under § 482. Conversely, when PBI's income is taxed at the standard Irish trading rate of 12.5%, the deemed-paid credits nearly eliminate the U.S. GILTI tax, and the GILTI offset from a § 482 adjustment is correspondingly small.

PBI's allocation of income between the KDB rate and the standard trading rate varies by year and depends on the proportion of PBI's income that qualifies as income from "qualifying assets" under the Irish Finance Act 2015, Part 29A. Based on PBI's Irish tax returns and the KDB claims filed for FY 2016–2020, we estimate that approximately 60%–70% of PBI's tested income is subject to the KDB rate, with the balance subject to the standard 12.5% rate. A blended analysis using a 65/35 KDB/standard split yields an approximate GILTI offset of approximately $0.037–$0.040 per dollar of § 482 adjustment, implying a net incremental tax cost of approximately $0.170–$0.173 per dollar of adjustment for TY 2018–2020.

Strategic Implication. The GILTI offset significantly reduces the effective cost of any IRC § 482 adjustment for TY 2018–2020, especially to the extent PBI's income is subject to the KDB rate of 6.25%. This reduction in effective cost should be factored into settlement analysis and hazards-of-litigation calculations. Specifically, when modeling the expected value of various settlement scenarios, the post-GILTI net tax cost should be used rather than the nominal 21% rate.

Caveat. The GILTI offset is available only if PPC properly claims conforming reductions to its GILTI inclusions for TY 2018–2020 in conjunction with any agreed or adjudicated § 482 adjustment. This is not an automatic adjustment. The IRS may not voluntarily allow conforming GILTI reductions when proposing § 482 adjustments, and PPC must affirmatively assert its right to such reductions. Procedurally, this will likely require the filing of amended Forms 8992 (U.S. Shareholder Calculation of GILTI) and amended Forms 5471 (Information Return of U.S. Persons With Respect to Certain Foreign Corporations) for each affected year, reflecting the reduced tested income for PBI. The defense team should ensure that any settlement agreement or closing agreement with the IRS explicitly provides for these conforming adjustments.

D. GILTI High-Tax Exclusion

Treas. Reg. § 1.951A-2(c)(7) provides an elective high-tax exclusion from GILTI. Under this regulation, a CFC shareholder may elect to exclude from tested income any item of gross income of a CFC that is subject to an effective foreign tax rate exceeding 90% of the maximum U.S. corporate rate. For TY 2018–2020 (at a 21% U.S. corporate rate), this threshold is 18.9% (i.e., 21% × 90%).

PBI's Irish effective tax rates — whether at the KDB rate of 6.25% or the standard trading rate of 12.5% — are well below the 18.9% high-tax exclusion threshold. Accordingly, the GILTI high-tax exclusion is not available for any portion of PBI's tested income, and PBI's full tested income (in excess of NDTIR) is subject to GILTI inclusion by PPC.

This conclusion is not affected by the IRS's proposed § 482 adjustments, which would reduce PBI's tested income but would not change the Irish effective tax rate applicable to PBI's remaining income.

VI. BEAT Regime (IRC § 59A) — Interaction with Transfer Pricing Adjustments

A. Overview of BEAT

The Base Erosion and Anti-Abuse Tax ("BEAT"), enacted by TCJA § 14401 and codified at IRC § 59A, imposes a minimum tax on certain U.S. corporations that make substantial deductible payments to related foreign persons. The BEAT is designed to address base erosion through outbound payments that reduce U.S. taxable income.

The BEAT applies to "applicable taxpayers," defined under IRC § 59A(e) as domestic corporations (other than regulated investment companies, real estate investment trusts, and S corporations) that satisfy two conditions: (1) average annual gross receipts of at least $500 million for the three-taxable-year period ending with the preceding taxable year; and (2) a "base erosion percentage" of 3% or more (2% for banks and registered securities dealers) for the taxable year.

The BEAT is computed by comparing the taxpayer's regular tax liability (determined without regard to credits other than the research credit and certain other specified credits) to a percentage of the taxpayer's "modified taxable income." Modified taxable income is the taxpayer's taxable income computed without regard to any base erosion tax benefit or the base erosion percentage of any net operating loss deduction. The BEAT rate is:

• 5% for taxable years beginning in calendar year 2018;

• 10% for taxable years beginning in calendar years 2019 through 2025; and

• 12.5% for taxable years beginning after December 31, 2025.

A "base erosion payment" is defined under IRC § 59A(d) as any amount paid or accrued by the taxpayer to a related foreign person that is deductible under the Code, that results in a reduction of the gross receipts of the taxpayer, or that is paid in connection with the acquisition of depreciable or amortizable property.

B. PPC's BEAT Applicability

PPC's average annual gross receipts for the relevant three-year period substantially exceed the $500 million threshold. With FY 2020 consolidated revenue of $6.82 billion, PPC clearly satisfies the gross receipts test and is potentially an "applicable taxpayer" for BEAT purposes, subject to the 3% base erosion percentage test.

The determination of whether PPC is an "applicable taxpayer" for BEAT purposes requires an analysis of PPC's "base erosion percentage" — the ratio of base erosion tax benefits to total deductions for the taxable year. This requires identification of all payments made by PPC to related foreign persons that are deductible or otherwise reduce PPC's gross receipts.

In evaluating PPC's intercompany payment flows for BEAT purposes, the following observations are pertinent:

CSA cost-sharing payments. Under the CSA, cost-sharing payments flow from PBI to PPC — not from PPC to PBI. PBI bears its share of intangible development costs by making payments to PPC proportional to PBI's reasonably anticipated benefits. These inbound payments increase PPC's U.S. taxable income and do not constitute base erosion payments by PPC.

Royalty payments. Similarly, the royalty payments under the legacy IP license flow from PBI to PPC. PBI pays PPC a royalty of 4.5% (as reported) of Non-Americas net sales. These inbound payments are not base erosion payments by PPC.

Other intercompany payments. PPC may make other intercompany payments to PBI or other foreign affiliates in the ordinary course of business, including management fees, corporate overhead allocations, or charges for shared services. To the extent such payments are deductible by PPC and are made to related foreign persons, they could constitute base erosion payments. However, such payments are not the subject of the current IRS examination, and their magnitude relative to PPC's total deductions must be evaluated to determine whether the 3% base erosion percentage threshold is met.

Key Analytical Point. The CSA and royalty arrangements that are the focus of the IRS's proposed IRC § 482 adjustments involve payments flowing from PBI to PPC — that is, inbound to the United States, not outbound. Accordingly, the core § 482 adjustments are unlikely to directly trigger additional BEAT liability for PPC. The BEAT is designed to address the erosion of the U.S. tax base through outbound deductible payments, not the understatement of inbound income.

C. Indirect BEAT Implications

Although the direct BEAT impact of the IRS's proposed § 482 adjustments is minimal, there are several indirect channels through which the adjustments could affect PPC's BEAT computation.

Impact on Modified Taxable Income. If the IRS's § 482 adjustments are sustained, the recharacterization of income from PBI to PPC would increase PPC's U.S. taxable income and, correspondingly, increase PPC's regular tax liability. Under the BEAT framework, a higher regular tax liability makes it less likely that the BEAT minimum tax will exceed the regular tax (since the BEAT applies only to the extent that the BEAT amount exceeds the regular tax). In this sense, the § 482 adjustments have an indirectly favorable effect on PPC's BEAT posture by raising the regular tax "floor" above which the BEAT would bite.

Cost-Sharing Payments from PPC to PBI. Under the CSA structure as described in Section III.A, cost-sharing payments flow from PBI to PPC. However, to the extent PPC makes any payments to PBI under the CSA — for example, if PPC reimburses PBI for intangible development costs incurred by PBI with respect to cost-shared intangibles developed by PBI — such payments could potentially be characterized as base erosion payments. PPC's position, based on a review of the CSA's payment flows, is that no material payments of this nature exist. PBI's role is primarily as a payor of cost-sharing contributions, not as a recipient of reimbursements from PPC for PBI-incurred development costs. This position should be confirmed with Crestfield & Associates.

Contract Manufacturing Arrangement. Penterra Manufacturing Ireland Limited ("PMI") is a wholly owned subsidiary of PBI that manufactures certain pharmaceutical products for PBI and PPC pursuant to a contract manufacturing arrangement at a cost-plus-8% markup. PMI is an Irish entity, and payments from PBI to PMI are between two Irish entities and do not directly involve PPC. However, if PPC makes any direct payments to PMI or other foreign affiliates for manufacturing services — for example, for contract manufacturing of products sold in the Americas — such payments could be base erosion payments by PPC. This issue should be examined in coordination with Crestfield & Associates (engagement partner: Martin Ogilvy, CPA) to confirm that PPC's direct payments to foreign affiliates for services are properly identified and quantified for BEAT computation purposes.

D. BEAT and the Correlative Offset

The $42.65 million correlative offset allowed by the IRS examination team to avoid double-counting between the CSA cost-sharing ratio adjustments and the royalty rate adjustments should be analyzed for any BEAT interaction. Specifically, the correlative offset reduces the net § 482 adjustment — and therefore the increase in PPC's taxable income — which could marginally reduce the favorable indirect BEAT effect described in Section VI.C above (i.e., the offset slightly reduces the increase in PPC's regular tax that would otherwise raise the BEAT floor).

However, given the direction of the core payment flows (inbound to the U.S.) and the absence of any direct base erosion payment component in the proposed adjustments, the BEAT impact of the correlative offset is expected to be minimal.

VII. FDII Regime (IRC § 250) — Potential Interaction

A. Overview. IRC § 250, enacted by TCJA § 14202, provides a deduction for "foreign-derived intangible income" ("FDII") that results in an effective U.S. tax rate of 13.125% on qualifying FDII (for taxable years beginning before January 1, 2026; 16.406% thereafter, when the deduction decreases from 37.5% to 21.875%). FDII is designed to incentivize U.S. corporations to retain intangible-income-generating activities in the United States by offering a preferential rate on income derived from serving foreign markets.

FDII is computed as the portion of a domestic corporation's "deemed intangible income" ("DII") that is attributable to foreign-derived income. DII is the excess of a corporation's "deduction eligible income" ("DEI") over a 10% deemed return on its QBAI. The foreign-derived portion is determined by the ratio of the corporation's "foreign-derived deduction eligible income" ("FDDEI") to its total DEI. FDDEI includes income from (i) the sale of property to foreign persons for foreign use and (ii) the provision of services to foreign persons or with respect to property located outside the United States.

B. Potential Interaction with § 482 Adjustments

If the IRS reallocates income from PBI to PPC under IRC § 482, some of that reallocated income could potentially qualify as FDII to the extent it is attributable to PPC's service of foreign markets. The logic underlying this argument is straightforward: the income that PBI was earning from Non-Americas sales was, by definition, income derived from serving foreign markets. If the IRS recharacterizes that income as properly belonging to PPC, PPC could argue that the recharacterized income constitutes FDDEI — income that PPC earned by providing intangible property (pharmaceutical IP) for foreign use.

However, the applicability of the FDII deduction to recharacterized § 482 income is subject to significant analytical complexity. The following issues must be addressed:

Related-Party Limitations. IRC § 250(b)(5)(B) provides specific rules for transactions with related parties. For sales of property to a related party, the property must be "for a foreign use" — that is, the property must ultimately be sold to an unrelated foreign person or used in connection with property that is sold to an unrelated foreign person, or the property must be used by the related party in the active conduct of a trade or business outside the United States. Royalty income received from a related CFC for the license of intangible property may qualify as FDDEI to the extent the related CFC uses the licensed intangible property in the active conduct of a trade or business outside the United States, provided the documentation requirements of Treas. Reg. § 1.250(b)-5 are satisfied.

Characterization of Recharacterized Income. The character of the recharacterized income for FDII purposes is unclear. If the IRS's adjustment takes the form of an increased royalty rate, the recharacterized income would be additional royalty income from PBI — which may qualify as FDDEI if PBI uses the licensed IP in the active conduct of its trade or business outside the United States. If the adjustment takes the form of an increased CSA cost-sharing ratio, the recharacterized income may be more properly characterized as additional cost-sharing payment income, the FDII treatment of which is less clear.

Computational Complexity. Even if a portion of the recharacterized income qualifies as FDDEI, the FDII deduction is computed based on the corporation's overall DEI, FDDEI, and QBAI. The addition of recharacterized income to PPC's DEI and FDDEI would require a full recomputation of PPC's FDII amount, which in turn depends on PPC's aggregate QBAI and total DEI for each year.

This is an area requiring further analysis, and we recommend that Whitmore Valuation Group be engaged to model the potential FDII benefit of recharacterized income under various adjustment scenarios. To the extent FDII treatment is available, it would partially offset the tax cost of any § 482 adjustment for TY 2018–2020 by reducing the effective rate on the recharacterized income from 21% to as low as 13.125%.

VIII. Transition-Year Issues: TY 2017

A. Pre-TCJA Rate and No GILTI/BEAT

TY 2017 occupies a unique position in the examination because it is subject to the pre-TCJA international tax regime in its entirety. The key features of the pre-TCJA regime as they bear on PPC's transfer pricing exposure are:

35% Corporate Rate. The federal corporate income tax rate applicable to TY 2017 is 35%, the highest rate in the examination period and 14 percentage points above the post-TCJA rate.

No GILTI. The GILTI regime under IRC § 951A is not in effect for TY 2017. PBI's income that is not "Subpart F income" under IRC §§ 951–964 (e.g., foreign base company sales income under IRC § 954(d) or foreign personal holding company income under IRC § 954(c)) is not currently taxable to PPC. To the extent PBI's pharmaceutical business income is derived from active business operations in Ireland and the Non-Americas Territory — as PPC's transfer pricing documentation and PBI's substance support — PBI's income is generally not Subpart F income and is subject to indefinite deferral until repatriated as a dividend.

No BEAT. The BEAT under IRC § 59A is not in effect for TY 2017.

No FDII. The FDII deduction under IRC § 250 is not available for TY 2017.

The absence of GILTI in TY 2017 is the most consequential difference for purposes of analyzing § 482 adjustment exposure. Because PBI's income was subject to deferral in TY 2017 (to the extent it was not Subpart F income), a § 482 adjustment that reallocates income from PBI to PPC for TY 2017 has no GILTI offset. PPC bears the full 35% rate on any reallocated income, without any mitigating reduction attributable to lower GILTI inclusions that PPC would otherwise have reported.

B. Comparative Exposure: TY 2017 vs. 2018–2020

The following table provides a comprehensive comparison of the effective tax cost per dollar of IRC § 482 adjustment across the examination years, incorporating the rate differential, the GILTI offset for TY 2018–2020, and the penalty exposure:

The differential is significant. TY 2017 adjustments are approximately 70% to 125% more costly on a per-dollar basis than TY 2018–2020 adjustments:

• Compared to the post-TCJA KDB scenario: $0.350 / $0.155 = 2.26x (i.e., TY 2017 is 126% more costly per dollar of adjustment).

• Compared to the post-TCJA standard rate scenario: $0.350 / $0.205 = 1.71x (i.e., TY 2017 is 71% more costly per dollar of adjustment).

• Including penalties, the differential is similar: $0.420 / $0.197 = 2.13x (KDB scenario) and $0.420 / $0.247 = 1.70x (standard rate scenario).

C. Transition Year Considerations

The TCJA transition tax under IRC § 965 — the mandatory repatriation of accumulated post-1986 deferred foreign earnings — may also interact with the IRS's proposed § 482 adjustments for TY 2017, creating a potentially beneficial secondary effect.

IRC § 965 applies to the last taxable year of a CFC beginning before January 1, 2018. For PBI, a calendar-year entity, this is PBI's fiscal year ending December 31, 2017. Under § 965, each U.S. shareholder of a CFC must include in income its pro rata share of the CFC's accumulated post-1986 deferred foreign income (the "§ 965(a) earnings amount"), measured as the greater of the CFC's accumulated post-1986 E&P as of November 2, 2017 or December 31, 2017.

If the IRS's § 482 adjustment for TY 2017 reduces PBI's income — which it does, because the adjustment reallocates income from PBI to PPC — then PBI's accumulated post-1986 E&P as of the measurement dates may be correspondingly reduced. A reduction in PBI's accumulated E&P would reduce PPC's § 965(a) earnings amount and, therefore, reduce PPC's transition tax liability under § 965.

The transition tax rate under § 965(c) is 15.5% on the portion of the § 965(a) earnings amount attributable to cash or cash-equivalent assets and 8% on the remainder. The potential reduction in PPC's § 965 liability from a conforming E&P reduction could partially offset the tax cost of the TY 2017 § 482 adjustment.

This beneficial interaction should be evaluated in detail, including: (i) the amount of PPC's § 965(a) earnings amount as originally reported; (ii) the portion attributable to PBI; (iii) the cash/non-cash split for purposes of the § 965(c) rate; and (iv) whether PPC elected to pay its § 965 liability in installments under § 965(h) and the implications of a retroactive reduction in the liability. This analysis should be coordinated with Crestfield & Associates, which prepared PPC's original § 965 computations.

IX. Impact on Settlement and Defense Strategy

A. Rate Differential in Settlement Calculations

Any settlement analysis must separately model the tax-dollar impact of adjustments for TY 2017 at the 35% rate and for TY 2018–2020 at the 21% rate. The GILTI offsets identified in Section V.C above must also be incorporated into the settlement model, as they materially affect the net tax cost of adjustments for the post-TCJA years.

The allocation of any global settlement adjustment across the four examination years is a critical variable. Because each dollar of TY 2017 adjustment carries approximately 70% to 125% more tax cost than a dollar of TY 2018–2020 adjustment (depending on PBI's Irish effective tax rate), PPC should seek, in any settlement negotiation, to allocate a disproportionate share of any aggregate concession to TY 2018–2020, where the per-dollar tax cost is lower. Conversely, PPC should seek to minimize the TY 2017 component of any settlement.

The settlement adjustment allocation across years should be modeled using a sensitivity analysis that varies the year-by-year allocation and computes the resulting aggregate tax cost under multiple scenarios. The defense team should prepare this analysis in advance of any settlement discussions, incorporating the rate differential, GILTI offsets at both the KDB and standard Irish rates, potential FDII benefits, and penalty exposure.

B. GILTI Offset as Defense Argument

The GILTI regime's partial offset to IRC § 482 adjustments may reduce the IRS's institutional incentive to pursue the full amount of the proposed adjustments for TY 2018–2020. From the government's perspective, the net revenue gain from a § 482 adjustment is not the headline 21% of the adjustment amount, but rather the net of the 21% incremental tax and the reduction in GILTI tax that would otherwise have been collected on PBI's income. At the KDB rate, this net revenue gain is only approximately $0.155 per dollar of adjustment, which is less than half the revenue gain that the same adjustment would produce for TY 2017 ($0.35 per dollar).

This economic reality may have persuasive value in Appeals negotiations. The IRS Office of Appeals considers the hazards of litigation and the expected government recovery in evaluating settlement proposals. By demonstrating that the government's net recovery from the TY 2018–2020 adjustments is substantially less than the nominal adjustment amount suggests, PPC may be able to negotiate a more favorable settlement posture.

Additionally, the GILTI offset argument may be useful in demonstrating that the IRS's proposed adjustments, if fully sustained, would produce a distorted result in which PPC's total U.S. tax liability (regular tax plus GILTI) actually decreases for PBI's operations while increasing for PPC's domestic operations — an outcome that arguably undermines the policy purpose of the § 482 adjustment, which is to ensure that the correct amount of income is attributed to U.S. activities.

C. BEAT Non-Applicability as Favorable Factor

As discussed in Section VI, the BEAT regime does not appear to create material additional exposure for PPC in connection with the IRS's proposed § 482 adjustments, because the core intercompany arrangements at issue involve inbound (not outbound) payments. This is a favorable factor for PPC's overall posture in the examination and in any settlement discussions.

The absence of BEAT exposure means that PPC does not face the "stacking" risk that some multinationals encounter in IRS examinations — i.e., the risk that § 482 adjustments could simultaneously trigger additional BEAT liability by increasing modified taxable income while decreasing base erosion tax benefits. PPC's payment flow structure — with cost-sharing payments and royalties flowing from PBI to PPC — avoids this risk entirely.

This favorable factor should be emphasized in any presentation to the IRS examination team or to Appeals, as it demonstrates that PPC's intercompany arrangements are structured in a manner that does not implicate the anti-base-erosion concerns that motivated the BEAT legislation.

X. Recommendations

Based on the foregoing analysis, we recommend the following actions:

1. TY 2017 Focus. Devote particular attention and defense resources to defending PPC's TY 2017 transfer pricing positions, given the 35% corporate tax rate applicable to that year and the absence of any GILTI offset to mitigate the tax cost of an adverse adjustment. The TY 2017 positions carry the highest per-dollar exposure of any examination year, and any concession on TY 2017 should be viewed as approximately twice as costly as a comparable concession on TY 2018–2020. The economic analyses being prepared by Whitmore Valuation Group should include a particularly robust defense of the arm's-length character of PPC's 2017 CSA cost-sharing ratios and legacy IP royalty rate.

2. GILTI Conforming Adjustments. Ensure that any settlement or agreed adjustment for TY 2018–2020 explicitly provides for corresponding reductions to PPC's GILTI inclusions on Forms 8992 and related schedules. The conforming GILTI adjustment is not automatic and must be affirmatively claimed by PPC. The settlement agreement or closing agreement should include specific language providing for the recomputation of PPC's GILTI inclusion amounts to reflect the reduced tested income of PBI resulting from the § 482 adjustment. Failure to secure this language could result in PPC bearing both the full § 482 tax and the unreduced GILTI tax — an impermissible double tax that the conforming adjustment mechanism is designed to prevent.

3. FDII Analysis. Commission further analysis from Whitmore Valuation Group on whether any portion of income recharacterized under § 482 could qualify as foreign-derived intangible income under IRC § 250, thereby benefiting from the reduced 13.125% effective rate. This analysis should model the FDII benefit under various recharacterization scenarios and should address the related-party limitations of IRC § 250(b)(5)(B) and the documentation requirements of the § 250 regulations.

4. § 965 Interaction. Analyze whether the IRS's proposed TY 2017 § 482 adjustment affects PBI's accumulated post-1986 earnings and profits for purposes of the § 965 transition tax. If the adjustment reduces PBI's E&P, PPC may be entitled to a conforming reduction in its § 965 inclusion amount and a corresponding refund of transition tax overpayment. This analysis should be coordinated with Crestfield & Associates, which prepared PPC's original § 965 computations and has access to the detailed E&P schedules and cash position data necessary for the calculation.

5. BEAT Monitoring. Continue to monitor PPC's base erosion percentage on an annual basis to confirm that PPC does not cross the 3% threshold that would make it an "applicable taxpayer" for BEAT purposes. This monitoring should be conducted in coordination with Crestfield & Associates (engagement partner: Martin Ogilvy, CPA) and should include a review of all intercompany payments from PPC to foreign affiliates, including management fees, service charges, and any cost-sharing payments flowing from PPC to PBI or other foreign entities. If PPC's base erosion percentage approaches the 3% threshold, additional BEAT planning and analysis may be warranted.

6. Settlement Modeling. Incorporate the rate differential, GILTI offsets, potential FDII benefits, § 965 interaction, and all other TCJA-related considerations into the sensitivity analysis and settlement range modeling being prepared for the defense. The settlement model should compute the aggregate tax cost of various adjustment scenarios, allocating adjustments across TY 2017–2020 in varying proportions, and should identify the allocation that minimizes PPC's total federal tax exposure for any given global settlement amount. This modeling should be completed prior to any substantive settlement discussions with the IRS examination team or Appeals.

XI. Conclusion

The Tax Cuts and Jobs Act significantly reduces Penterra Pharmaceuticals Corp.'s per-dollar transfer pricing exposure for TY 2018–2020 compared to TY 2017, operating through two principal mechanisms. First, the rate reduction from 35% to 21% directly reduces the federal income tax attributable to each dollar of IRC § 482 adjustment by 40%. Second, the GILTI regime's interaction with § 482 adjustments creates a partial offset: because any adjustment that reallocates income from PBI to PPC simultaneously reduces PPC's GILTI inclusion on PBI's excess intangible income, the net incremental tax cost of each dollar of adjustment is further reduced from $0.21 to approximately $0.155–$0.205 per dollar (depending on PBI's Irish effective tax rate under the Knowledge Development box and standard trading rate).

The BEAT regime does not create material additional exposure for PPC in connection with the current examination, given the inbound direction of the intercompany payment flows at issue (cost-sharing payments and royalties flowing from PBI to PPC). The FDII deduction under IRC § 250 may provide an additional partial offset to the tax cost of any § 482 adjustment, but this requires further analysis of the recharacterized income's eligibility for FDII treatment.

TY 2017 remains the most consequential examination year on a per-dollar basis, with no GILTI offset, no FDII benefit, and a 35% federal rate. The § 965 transition tax interaction presents a potential countervailing benefit that warrants further investigation.

These dynamics should be integrated into both the economic analysis being coordinated with Whitmore Valuation Group LLC and the defense strategy being developed under Leonard Cross's direction. The rate differential and GILTI offset, in particular, should inform the allocation of defense resources across examination years, the structure of any settlement proposal, and the hazards-of-litigation analysis presented to the IRS Office of Appeals.

This memorandum should be read in conjunction with:

• The preliminary assessment memorandum dated June 15, 2022;

• The defense strategy memorandum dated July 12, 2022; and

• The CSA regulatory analysis memorandum dated August 5, 2022.

This memorandum has been prepared for

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
MEMORANDUM
TO: Leonard Cross, Responsible Partner, Tax Department Garrett Simmons, Lead Associate, Tax Department
FROM: Leila Nazari, Working Associate, Tax Department
DATE: August 25, 2022
RE: Impact of the Tax Cuts and Jobs Act on Penterra Pharmaceuticals Corp.'s Transfer Pricing Positions — Tax Years 2017 vs. 2018–2020
MATTER NO.: 1018-00009
CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
Right-click to update Table of Contents
I. Executive Summary
This memorandum analyzes the impact of the Tax Cuts and Jobs Act ("TCJA"), Pub. L. No. 115-97, 131 Stat. 2054 (2017), effective January 1, 2018, on the transfer pricing positions of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") that are currently under examination by the Internal Revenue Service (IRS Exam Team ID: LB&I-NE-TP-2022-00641, covering tax years 2017 through 2020). The purpose of this memorandum is to provide a comprehensive legal analysis of the TCJA's operative provisions as they bear on PPC's transfer pricing exposure, to quantify the differential impact of IRS proposed adjustments across the pre-TCJA and post-TCJA periods, and to identify the strategic implications for PPC's defense posture.
The TCJA fundamentally altered the U.S. international tax landscape through several provisions of direct relevance to PPC's examination:
(a) the reduction of the federal corporate income tax rate from 35% to 21%, effective for tax years beginning after December 31, 2017, under IRC § 11(b) as amended;
(b) the enactment of the Global Intangible Low-Taxed Income ("GILTI") regime under IRC § 951A, which requires U.S. shareholders of controlled foreign corporations ("CFCs") to include currently in gross income the CFC's income in excess of a deemed return on tangible assets, thereby ending indefinite deferral of CFC intangible income;
(c) the introduction of the Base Erosion and Anti-Abuse Tax ("BEAT") under IRC § 59A, which imposes a minimum tax on U.S. corporations making deductible payments to related foreign persons; and
(d) modifications to the treatment of foreign-derived intangible income ("FDII") under IRC § 250, which provides a preferential effective rate of 13.125% for qualifying domestic income attributable to foreign markets.
These changes create a materially different exposure profile for TY 2017 (the last pre-TCJA year, subject to the 35% corporate rate and the traditional deferral regime) versus TY 2018–2020 (the post-TCJA period, subject to the 21% corporate rate and the new anti-base-erosion provisions). The differential affects both the quantum of any IRC § 482 adjustments on a tax-dollar basis and the interaction of such adjustments with the GILTI, BEAT, and FDII regimes.
The IRS has communicated proposed net adjustments totaling approximately $380.4 million across all four examination years. These proposed adjustments relate to PPC's cost-sharing arrangement ("CSA") with its Irish subsidiary, Penterra Biopharma International DAC ("PBI"), and to the royalty rate under a separate legacy IP license between PPC and PBI. The TCJA's rate reduction from 35% to 21% means that the per-dollar federal income tax impact of adjustments for TY 2018–2020 is approximately 40% lower than for TY 2017. However, the GILTI regime may partially offset this benefit by imposing additional U.S. tax on PBI's income that was previously subject to indefinite deferral — although, critically, this GILTI effect also operates in reverse, such that any IRC § 482 adjustment that reduces PBI's tested income simultaneously reduces PPC's GILTI inclusion, creating a partial offset to the adjustment's tax cost.
The BEAT regime, while potentially applicable to PPC given its gross receipts, does not appear to create material additional exposure in this examination because the core intercompany payment flows at issue (cost-sharing payments and royalties) are inbound to the United States — that is, they flow from PBI to PPC — rather than constituting outbound base erosion payments from PPC to a related foreign person.
Key Conclusion: The TCJA rate reduction substantially reduces PPC's aggregate transfer pricing exposure on a tax-dollar basis for TY 2018–2020, but introduces new analytical complexities — principally the GILTI inclusion offset and the need to confirm BEAT non-applicability — that must be addressed in the defense strategy. On a per-dollar-of-adjustment basis, TY 2017 exposure is approximately 70% to 125% more costly than TY 2018–2020 exposure, depending on the applicable Irish effective tax rate for PBI's income. This differential should inform the allocation of defense resources and the structure of any settlement.
II. Scope and Purpose
This memorandum is intended to serve the following purposes:
First, it analyzes the TCJA's impact across three critical dimensions of PPC's transfer pricing positions: (1) the statutory rate change from 35% to 21% and its effect on the dollar-exposure calculations associated with the IRS's proposed IRC § 482 adjustments; (2) the interaction between proposed IRC § 482 adjustments and the GILTI regime under IRC § 951A, including the mechanics by which a § 482 adjustment that reallocates income from PBI to PPC simultaneously reduces PPC's GILTI inclusion; and (3) the interaction between the proposed adjustments and the BEAT under IRC § 59A, including an assessment of whether the direction and character of the intercompany payment flows at issue could trigger BEAT liability.
Second, this memorandum is intended to inform the broader defense strategy being coordinated by Leonard Cross and Sylvia Hartwell of this firm, and the economic analyses being prepared by Whitmore Valuation Group LLC ("Whitmore") under the Kovel arrangement established pursuant to the engagement letter dated May 10, 2022 (Reference: 1018-00009-KV). Dr. Helena Vasquez serves as the lead economist for the Whitmore engagement. The economic analyses being prepared by Whitmore, including the comparability analysis and statistical benchmarking of arm's-length ranges for the CSA cost-sharing ratios and the legacy IP royalty rate, should incorporate the rate-differential and GILTI-offset considerations identified in this memorandum when computing the tax-dollar implications of various adjustment scenarios.
Third, this memorandum provides contextual background on PPC's corporate structure and the IRS's proposed adjustments for purposes of identifying the TCJA-related issues that bear on the defense. The following contextual facts inform the analysis:
PPC is a Delaware corporation headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. The Company's common stock is traded on the Nasdaq Stock Market under the ticker symbol PPCA. For its fiscal year ended December 31, 2020, PPC reported consolidated revenue of $6.82 billion and pre-tax income of $1.47 billion. PPC is a multinational pharmaceutical company with operations in the United States and, through its subsidiaries, in over 70 countries worldwide. Its core therapeutic areas include oncology, immunology, and rare diseases.
PPC's principal foreign subsidiary for purposes of this examination is Penterra Biopharma International DAC ("PBI"), a Designated Activity Company organized under the laws of Ireland. PBI is held through Penterra Holdings Luxembourg S.à r.l. ("PHL"), a Luxembourg entity registered with the Registre de Commerce et des Sociétés under Number B 168452. PHL is treated as a disregarded entity for U.S. federal income tax purposes pursuant to Treas. Reg. § 301.7701-3, and accordingly, PPC is treated as the direct U.S. shareholder of PBI for purposes of the Subpart F and GILTI provisions. This ownership structure and its implications for CFC status are discussed further in Section V.B below.
This memorandum does not address the merits of PPC's transfer pricing positions on a stand-alone basis (i.e., whether PPC's CSA cost-sharing ratios and legacy IP royalty rate satisfy the arm's-length standard under IRC § 482 and the regulations thereunder). Those issues are the subject of the preliminary assessment memorandum dated June 15, 2022, and the defense strategy memorandum dated July 12, 2022, and are being analyzed in detail in the economic reports under preparation by Whitmore. This memorandum focuses exclusively on the TCJA's impact on the tax-dollar consequences of the IRS's proposed adjustments and the strategic implications thereof.
III. Background: PPC's IP Structure and the IRS's Proposed Adjustments
A. The Cost-Sharing Arrangement and Royalty Structure
PBI was incorporated on March 15, 2012, under the laws of Ireland as a Designated Activity Company. On July 1, 2012, PPC and PBI entered into a qualified cost-sharing arrangement (the "CSA") within the meaning of Treas. Reg. § 1.482-7. The CSA governs the development and exploitation of PPC's pharmaceutical intellectual property outside the Americas territory.
Platform Contribution Transaction. In connection with the formation of the CSA, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC on July 1, 2012. This PCT payment represented compensation for PBI's buy-in to PPC's pre-existing intellectual property, which at the time consisted of a portfolio of clinical-stage and approved oncology compounds. The PCT payment was valued based on a discounted cash flow analysis prepared by PPC's then-transfer pricing advisors, which projected the future revenue streams attributable to the pre-existing IP in the non-Americas territory and discounted them to present value as of the buy-in date. The adequacy of the PCT payment is a separate issue under examination and is addressed in the CSA regulatory analysis memorandum dated August 5, 2022.
Scope of the CSA. Under the CSA, PBI acquired the rights to develop and commercially exploit PPC's pharmaceutical IP in all territories outside the Americas (i.e., the "Non-Americas Territory," comprising Europe, the Middle East, Africa, and Asia-Pacific) in exchange for the initial PCT payment and ongoing cost-sharing payments proportional to reasonably anticipated benefits ("RAB"). PPC retained the rights to develop and exploit the same IP in the Americas (i.e., the United States, Canada, Mexico, and Central and South America). The CSA covers all intangible development activities ("IDAs") undertaken by either party that relate to the development of pharmaceutical products within the scope of the arrangement.
Cost-Sharing Percentages. PBI's cost-sharing percentages, reflecting its share of total intangible development costs under the CSA, increased over the examination period in line with the growth of PBI's reasonably anticipated benefits from the covered intangibles. The following table summarizes PBI's cost-sharing contributions for TY 2017–2020:
The gradual increase in PBI's cost-sharing percentage reflects the growing share of global pharmaceutical revenue attributable to the Non-Americas Territory during the examination period, driven in part by PBI's successful commercialization of PPC's key products in European and Asia-Pacific markets.
Legacy IP License. In addition to the CSA, PBI holds a separate license from PPC for pre-2012 vintage compounds — that is, pharmaceutical products that were fully approved and on the market prior to the establishment of the CSA on July 1, 2012, and that were therefore excluded from the CSA's scope. Under this legacy IP license, PBI pays PPC a royalty at a rate of 4.5% of net sales for the Non-Americas Territory. The legacy compound net sales and corresponding royalty payments for the examination period are as follows:
The decline in legacy compound net sales over the examination period reflects the natural lifecycle of older pharmaceutical products, including loss of patent exclusivity and generic competition in certain Non-Americas markets.
PBI's Functions and Economic Substance. PBI maintains significant economic substance in Ireland. As of December 31, 2020, PBI employed 185 full-time employees, up from 52 employees at the time of incorporation in 2012. PBI's offices are located at Sandyford Business Park, Dublin, Ireland, comprising approximately 18,000 square feet of leased office space. PBI's employees perform a range of functions, including regulatory affairs, medical affairs, commercial operations management, pharmacovigilance, supply chain coordination, market access, and general management.
PBI's Managing Director is Aidan Naughton, who has served in that capacity since 2014. The PBI board of directors held a total of 42 board meetings during the TY 2017–2020 examination period, with meetings occurring approximately quarterly but with additional sessions convened for significant commercial and regulatory decisions. PBI has incurred cumulative regulatory expenditures of approximately €47.2 million during the period from incorporation through the end of 2020, reflecting its active engagement with regulatory authorities across 68 country markets in the Non-Americas Territory.
PBI exercises independent pricing authority across its 68 country markets, establishing prices for PPC's pharmaceutical products based on local market conditions, reimbursement frameworks, competitive dynamics, and regulatory requirements. PBI's pricing decisions are made by its commercial operations team in Dublin, subject to oversight by the PBI board.
Key Products. The principal products generating revenue for PPC and PBI during the examination period include:
• Veritaxol (oncology): Global revenue of $3.12 billion (FY 2020), of which $1.34 billion was attributable to the Non-Americas Territory. Veritaxol is PPC's flagship oncology product, approved for the treatment of non-small cell lung cancer and certain hematological malignancies.
• Imvara (immunology): Global revenue of $1.87 billion (FY 2020), of which $0.79 billion was attributable to the Non-Americas Territory. Imvara is a biologic product approved for the treatment of moderate-to-severe rheumatoid arthritis and psoriatic arthritis.
• Cerulon (rare disease): Global revenue of $0.62 billion (FY 2020), of which $0.28 billion was attributable to the Non-Americas Territory. Cerulon is an enzyme replacement therapy for a rare lysosomal storage disorder.
Irish Tax Position. PBI has claimed benefits under Ireland's Knowledge Development box ("KDB") regime at an effective tax rate of 6.25% on qualifying intellectual property income from its fiscal year ending December 31, 2016 forward. Income not qualifying for the KDB is subject to the standard Irish corporation tax trading rate of 12.5%. The allocation of PBI's income between the KDB rate and the standard trading rate is relevant to the computation of foreign tax credits under IRC § 960 and the quantification of the GILTI offset, as discussed in Section V.C below.
B. The IRS's Proposed Adjustments
The IRS Large Business & International Division ("LB&I") examination team has proposed aggregate net adjustments totaling approximately $380.4 million across TY 2017–2020. The proposed adjustments fall into two principal categories, with a correlative offset to avoid double-counting:
CSA Cost-Sharing Ratio Adjustments. The IRS proposes to increase PBI's cost-sharing ratio under the CSA by 8 to 12 percentage points for each examination year, asserting that PBI's reasonably anticipated benefits from the covered intangibles are higher than reported on PPC's returns. The effect of this adjustment is to reallocate a greater share of intangible development costs to PBI, correspondingly increasing PPC's U.S. taxable income. The proposed CSA adjustments total $235.01 million across the four years, as follows:
Royalty Rate Adjustments. The IRS proposes to increase the royalty rate on the legacy IP license from 4.5% to 11.0% of Non-Americas net sales, asserting that PPC's 4.5% rate is below the arm's-length range for comparable licensing transactions involving pharmaceutical IP of similar value and risk profile. The proposed royalty adjustments total $188.04 million across the four years:
Correlative Offset. The IRS examination team has allowed a correlative offset of $42.65 million to avoid double-counting between the CSA cost-sharing ratio adjustments and the royalty rate adjustments, which arise from overlapping bases of income reallocation. This correlative offset reduces the net proposed adjustment from the gross total of $423.05 million ($235.01M + $188.04M) to $380.4 million.
Proposed Penalties. The IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty at the 20% rate on the underpayment attributable to the net § 482 allocation. Based on the IRS's proposed adjustments, the penalty exposure is calculated as $380.4 million × 21% × 20% = $15.98 million. The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h), which would apply if the price for any property or services is 400% or more (or 25% or less) of the correct price.
Status of Examination. A Notice of Proposed Adjustment ("NOPA") was issued on October 12, 2023. However, this memorandum was prepared in August 2022, and the proposed adjustments described herein are based on the early-stage analysis of potential IRS positions as communicated during the examination opening conference held on June 28, 2022. The figures set forth above reflect our best assessment of the likely scope and magnitude of the IRS's positions as of the date of this memorandum and may be refined as the examination progresses.
IV. The TCJA Rate Change: Impact on Transfer Pricing Exposure
A. Corporate Tax Rate Reduction
The most immediately consequential change enacted by the TCJA for purposes of PPC's transfer pricing examination is the reduction of the federal corporate income tax rate from 35% to 21%. This rate change, codified in IRC § 11(b) as amended by TCJA § 13001, applies to taxable years beginning after December 31, 2017.
For TY 2017, the applicable federal corporate tax rate is 35% for the full taxable year. PPC's fiscal year ends on December 31, and accordingly, PPC's 2017 taxable year began on January 1, 2017 — before the TCJA's effective date. The TCJA rate reduction therefore does not apply to TY 2017 under any theory, including the blended-rate provision of former IRC § 15 (which applied only to fiscal-year taxpayers whose taxable year straddled the January 1, 2018 effective date). Since PPC is a calendar-year taxpayer, no blended rate applies.
For TY 2018 through TY 2020, the applicable federal corporate tax rate is 21%. This rate applies uniformly across all three post-TCJA examination years.
The 14-percentage-point reduction in the corporate rate from 35% to 21% represents a 40% decrease in the federal tax cost of each dollar of IRC § 482 adjustment. This fundamental arithmetic drives much of the analysis that follows.
B. Dollar-Impact Analysis by Tax Year
The rate differential between TY 2017 and TY 2018–2020 has a direct and substantial impact on the federal income tax consequences of the IRS's proposed adjustments. The following analysis quantifies this impact on the assumption that the IRS's full proposed adjustments are sustained.
TY 2017. The IRS's proposed adjustments for TY 2017 consist of a CSA cost-sharing ratio adjustment of $48.73 million and a royalty rate adjustment of $52.95 million, less an allocable portion of the $42.65 million correlative offset. The net proposed adjustment for TY 2017 is approximately $59.03 million (after allocation of the correlative offset on a pro rata basis across all four years). At the 35% federal corporate rate, the federal income tax attributable to the TY 2017 adjustment would be approximately $20.66 million.
TY 2018–2020. The IRS's proposed adjustments for the three post-TCJA years total approximately $321.37 million in the aggregate (the balance of the $380.4 million total after allocation of $59.03 million to TY 2017). At the 21% federal corporate rate, the federal income tax attributable to the TY 2018–2020 adjustments would be approximately $67.49 million.
The following table illustrates the differential tax impact per dollar of IRC § 482 adjustment:
Strategic Observation. The rate differential means that any concession or adverse determination on TY 2017 carries a disproportionately high tax cost relative to the same dollar amount of concession for TY 2018–2020. Specifically, each dollar of adjustment sustained for TY 2017 produces $0.14 more in federal tax liability than the same dollar of adjustment sustained for TY 2018, 2019, or 2020. Defense resources should therefore be particularly focused on minimizing any TY 2017 adjustment, all else being equal.
However, it is important to note that the overall dollar volume of the IRS's proposed adjustments is lower for TY 2017 than for any individual post-TCJA year. The TY 2017 gross adjustment (before correlative offset) is $101.68 million ($48.73M CSA + $52.95M royalty), compared to $107.16 million for TY 2018, $107.82 million for TY 2019, and $106.39 million for TY 2020. This partially mitigates the per-dollar rate disadvantage, though the net effect still favors prioritizing the TY 2017 defense.
C. Penalty Rate Interaction
The IRC § 6662(e) substantial valuation misstatement penalty is computed as 20% of the underpayment of tax attributable to the substantial valuation misstatement. Because the penalty is calculated on the tax attributable to the adjustment (not on the adjustment itself), the TCJA rate reduction also reduces the penalty exposure per dollar of adjustment for TY 2018–2020.
• At 35% (TY 2017): The penalty per dollar of § 482 adjustment is $0.07 (i.e., $1.00 × 35% × 20% = $0.07).
• At 21% (TY 2018–2020): The penalty per dollar of § 482 adjustment is $0.042 (i.e., $1.00 × 21% × 20% = $0.042).
Thus, the penalty cost per dollar of adjustment is also 40% lower for the post-TCJA years.
As noted above, the IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h). The 40% penalty would apply if the transfer price used by PPC is 400% or more (or 25% or less) of the arm's-length price. While PPC's positions represent meaningful deviations from the IRS's proposed arm's-length prices, the magnitude of the deviations does not appear to reach the 400%/25% threshold for any individual transaction.
PPC's contemporaneous transfer pricing documentation was prepared by Crestfield & Associates LLP (transfer pricing partner: Susan Lam, CPA) and covers all four examination years. This documentation provides a basis for penalty protection under IRC § 6662(e)(3)(B), which requires that the taxpayer have maintained contemporaneous documentation establishing that the transfer pricing method selected and applied was reasonable and that the taxpayer reasonably concluded that the method provided the most reliable measure of an arm's-length result. We have reviewed the Crestfield documentation and believe it satisfies the reasonable-cause-and-good-faith standard for penalty protection purposes, subject to the caveats identified in the defense strategy memorandum dated July 12, 2022.
V. GILTI Regime (IRC § 951A) — Interaction with Transfer Pricing Adjustments
A. Overview of GILTI
The GILTI regime, enacted by TCJA § 14201 and codified at IRC § 951A, represents one of the most significant structural changes to the U.S. international tax system effected by the TCJA. GILTI is effective for taxable years of foreign corporations beginning after December 31, 2017, and for taxable years of U.S. shareholders in which or with which such taxable years of foreign corporations end. For PPC, which is a calendar-year taxpayer and the U.S. shareholder of the calendar-year CFC PBI, the GILTI regime applies beginning with TY 2018.
The GILTI regime requires each U.S. shareholder of a CFC to include in gross income, on a current basis, its pro rata share of the CFC's "GILTI inclusion amount." The GILTI inclusion amount is computed as follows:
GILTI = Excess of:
(i) the U.S. shareholder's aggregate pro rata share of the "tested income" of each CFC, over
(ii) the U.S. shareholder's "net deemed tangible income return" ("NDTIR"), which equals 10% of the shareholder's aggregate pro rata share of the "qualified business asset investment" ("QBAI") of each CFC, reduced by certain interest expense allocable to the CFC's tested income.
In practical terms, GILTI operates to tax currently the income of CFCs that exceeds a 10% deemed return on the CFC's tangible depreciable assets. For a pharmaceutical company like PBI, whose income is overwhelmingly derived from intangible assets (pharmaceutical IP) rather than tangible assets, the GILTI regime captures the vast majority of PBI's income as "tested income" in excess of the QBAI-based return.
IRC § 250(a)(1)(B) provides a deduction equal to 50% of a domestic corporation's GILTI inclusion amount (applicable for taxable years beginning after December 31, 2017 and before January 1, 2026; the deduction reduces to 37.5% for taxable years beginning after December 31, 2025). This deduction results in an effective U.S. tax rate on GILTI of 10.5% (i.e., 21% × 50% = 10.5%), before the application of foreign tax credits.
IRC § 960(d) allows a deemed-paid foreign tax credit equal to 80% of the foreign income taxes properly attributable to the tested income of the CFC that gives rise to the GILTI inclusion. This 80% haircut on deemed-paid credits (compared to the 100% credit historically available under pre-TCJA § 960 for Subpart F inclusions) is a deliberate design feature of the GILTI regime intended to ensure that some residual U.S. tax is imposed on CFC income even when that income is subject to foreign taxation.
B. PBI's Status as a CFC
PBI is a Designated Activity Company organized under the laws of Ireland, with its registered office at Sandyford Business Park, Dublin, Ireland. PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), which is in turn 100% owned by PPC. PHL, as noted in Section II above, is classified as a disregarded entity for U.S. federal income tax purposes under the check-the-box regulations of Treas. Reg. § 301.7701-3. As a consequence of PHL's disregarded status, PPC is treated for all purposes of the Internal Revenue Code as the direct owner of PBI's outstanding shares.
PBI is therefore a "controlled foreign corporation" within the meaning of IRC § 957(a), as PPC — a single United States shareholder within the meaning of IRC § 951(b) — owns 100% of the total combined voting power and 100% of the total value of PBI's outstanding stock. PPC's status as a "United States shareholder" under § 951(b) is established by its ownership of more than 10% of the total combined voting power of PBI.
PBI has significant "tested income" for GILTI purposes. For its fiscal year ended December 31, 2020, PBI reported pre-tax income of approximately €1.06 billion (approximately $1.16 billion at average 2020 EUR/USD exchange rates). PBI's QBAI — consisting of its depreciable tangible assets — is modest relative to its total income, as PBI's business model is intangible-asset-intensive and relies primarily on licensed and co-developed pharmaceutical intellectual property rather than owned manufacturing facilities or equipment. PBI's tested income therefore substantially exceeds its NDTIR (10% of QBAI), resulting in a significant GILTI inclusion for PPC in each post-TCJA year.
C. Impact of IRC § 482 Adjustments on GILTI
The interaction between IRC § 482 adjustments and the GILTI regime is a critical analytical issue for PPC's defense strategy. The mechanics of this interaction are as follows:
If the IRS increases PPC's U.S.-source income under IRC § 482 — by reallocating income from PBI to PPC through an increase in CSA cost-sharing ratios or an increase in the legacy IP royalty rate — the direct effect is to increase PPC's taxable income as reported on its U.S. federal income tax return. However, the correlative effect is to decrease PBI's income (and therefore PBI's "tested income" for GILTI purposes) by a corresponding amount, assuming that proper correlative or conforming adjustments are made to PBI's earnings and profits and tested income computations.
This creates a partial offset mechanism: the additional U.S. tax from the § 482 adjustment is partially mitigated by the reduction in the GILTI tax that PPC would otherwise have paid on PBI's excess intangible income. In essence, because the GILTI regime already imposes U.S. tax on PBI's income (albeit at a reduced effective rate), each dollar of income reallocated from PBI to PPC under § 482 does not create a full incremental $0.21 tax liability — instead, the incremental cost is $0.21 minus the GILTI tax that PPC would have paid on that same dollar had it remained with PBI.
The magnitude of this GILTI offset depends on the effective Irish tax rate applicable to PBI's income, because the Irish taxes paid by PBI on its income generate deemed-paid foreign tax credits under IRC § 960(d) that reduce the U.S. GILTI tax. The quantification is as follows:
For each $1 of IRC § 482 adjustment for TY 2018–2020:
Additional U.S. tax from the § 482 adjustment: $0.21 (at the 21% corporate rate).
Reduced GILTI inclusion (net of § 250 deduction and § 960 foreign tax credit):
The net U.S. GILTI tax on $1 of PBI income depends on the applicable Irish effective tax rate:
(i) KDB rate (6.25%): GILTI tax per $1 of PBI income = $1.00 × 10.5% (effective U.S. GILTI rate after § 250 deduction) minus ($0.0625 × 80%) (deemed-paid credit at 80% of Irish tax) = $0.105 − $0.050 = $0.055 per dollar.
(ii) Standard trading rate (12.5%): GILTI tax per $1 of PBI income = $1.00 × 10.5% minus ($0.125 × 80%) = $0.105 − $0.100 = $0.005 per dollar.
Net incremental U.S. tax from $1 of § 482 adjustment (after GILTI offset):
The GILTI offset is substantially more significant when PBI's income is taxed at the KDB rate of 6.25%, because the lower Irish tax rate produces smaller deemed-paid foreign tax credits, leaving a larger residual U.S. GILTI tax that is eliminated when the income is reallocated to PPC under § 482. Conversely, when PBI's income is taxed at the standard Irish trading rate of 12.5%, the deemed-paid credits nearly eliminate the U.S. GILTI tax, and the GILTI offset from a § 482 adjustment is correspondingly small.
PBI's allocation of income between the KDB rate and the standard trading rate varies by year and depends on the proportion of PBI's income that qualifies as income from "qualifying assets" under the Irish Finance Act 2015, Part 29A. Based on PBI's Irish tax returns and the KDB claims filed for FY 2016–2020, we estimate that approximately 60%–70% of PBI's tested income is subject to the KDB rate, with the balance subject to the standard 12.5% rate. A blended analysis using a 65/35 KDB/standard split yields an approximate GILTI offset of approximately $0.037–$0.040 per dollar of § 482 adjustment, implying a net incremental tax cost of approximately $0.170–$0.173 per dollar of adjustment for TY 2018–2020.
Strategic Implication. The GILTI offset significantly reduces the effective cost of any IRC § 482 adjustment for TY 2018–2020, especially to the extent PBI's income is subject to the KDB rate of 6.25%. This reduction in effective cost should be factored into settlement analysis and hazards-of-litigation calculations. Specifically, when modeling the expected value of various settlement scenarios, the post-GILTI net tax cost should be used rather than the nominal 21% rate.
Caveat. The GILTI offset is available only if PPC properly claims conforming reductions to its GILTI inclusions for TY 2018–2020 in conjunction with any agreed or adjudicated § 482 adjustment. This is not an automatic adjustment. The IRS may not voluntarily allow conforming GILTI reductions when proposing § 482 adjustments, and PPC must affirmatively assert its right to such reductions. Procedurally, this will likely require the filing of amended Forms 8992 (U.S. Shareholder Calculation of GILTI) and amended Forms 5471 (Information Return of U.S. Persons With Respect to Certain Foreign Corporations) for each affected year, reflecting the reduced tested income for PBI. The defense team should ensure that any settlement agreement or closing agreement with the IRS explicitly provides for these conforming adjustments.
D. GILTI High-Tax Exclusion
Treas. Reg. § 1.951A-2(c)(7) provides an elective high-tax exclusion from GILTI. Under this regulation, a CFC shareholder may elect to exclude from tested income any item of gross income of a CFC that is subject to an effective foreign tax rate exceeding 90% of the maximum U.S. corporate rate. For TY 2018–2020 (at a 21% U.S. corporate rate), this threshold is 18.9% (i.e., 21% × 90%).
PBI's Irish effective tax rates — whether at the KDB rate of 6.25% or the standard trading rate of 12.5% — are well below the 18.9% high-tax exclusion threshold. Accordingly, the GILTI high-tax exclusion is not available for any portion of PBI's tested income, and PBI's full tested income (in excess of NDTIR) is subject to GILTI inclusion by PPC.
This conclusion is not affected by the IRS's proposed § 482 adjustments, which would reduce PBI's tested income but would not change the Irish effective tax rate applicable to PBI's remaining income.
VI. BEAT Regime (IRC § 59A) — Interaction with Transfer Pricing Adjustments
A. Overview of BEAT
The Base Erosion and Anti-Abuse Tax ("BEAT"), enacted by TCJA § 14401 and codified at IRC § 59A, imposes a minimum tax on certain U.S. corporations that make substantial deductible payments to related foreign persons. The BEAT is designed to address base erosion through outbound payments that reduce U.S. taxable income.
The BEAT applies to "applicable taxpayers," defined under IRC § 59A(e) as domestic corporations (other than regulated investment companies, real estate investment trusts, and S corporations) that satisfy two conditions: (1) average annual gross receipts of at least $500 million for the three-taxable-year period ending with the preceding taxable year; and (2) a "base erosion percentage" of 3% or more (2% for banks and registered securities dealers) for the taxable year.
The BEAT is computed by comparing the taxpayer's regular tax liability (determined without regard to credits other than the research credit and certain other specified credits) to a percentage of the taxpayer's "modified taxable income." Modified taxable income is the taxpayer's taxable income computed without regard to any base erosion tax benefit or the base erosion percentage of any net operating loss deduction. The BEAT rate is:
• 5% for taxable years beginning in calendar year 2018;
• 10% for taxable years beginning in calendar years 2019 through 2025; and
• 12.5% for taxable years beginning after December 31, 2025.
A "base erosion payment" is defined under IRC § 59A(d) as any amount paid or accrued by the taxpayer to a related foreign person that is deductible under the Code, that results in a reduction of the gross receipts of the taxpayer, or that is paid in connection with the acquisition of depreciable or amortizable property.
B. PPC's BEAT Applicability
PPC's average annual gross receipts for the relevant three-year period substantially exceed the $500 million threshold. With FY 2020 consolidated revenue of $6.82 billion, PPC clearly satisfies the gross receipts test and is potentially an "applicable taxpayer" for BEAT purposes, subject to the 3% base erosion percentage test.
The determination of whether PPC is an "applicable taxpayer" for BEAT purposes requires an analysis of PPC's "base erosion percentage" — the ratio of base erosion tax benefits to total deductions for the taxable year. This requires identification of all payments made by PPC to related foreign persons that are deductible or otherwise reduce PPC's gross receipts.
In evaluating PPC's intercompany payment flows for BEAT purposes, the following observations are pertinent:
CSA cost-sharing payments. Under the CSA, cost-sharing payments flow from PBI to PPC — not from PPC to PBI. PBI bears its share of intangible development costs by making payments to PPC proportional to PBI's reasonably anticipated benefits. These inbound payments increase PPC's U.S. taxable income and do not constitute base erosion payments by PPC.
Royalty payments. Similarly, the royalty payments under the legacy IP license flow from PBI to PPC. PBI pays PPC a royalty of 4.5% (as reported) of Non-Americas net sales. These inbound payments are not base erosion payments by PPC.
Other intercompany payments. PPC may make other intercompany payments to PBI or other foreign affiliates in the ordinary course of business, including management fees, corporate overhead allocations, or charges for shared services. To the extent such payments are deductible by PPC and are made to related foreign persons, they could constitute base erosion payments. However, such payments are not the subject of the current IRS examination, and their magnitude relative to PPC's total deductions must be evaluated to determine whether the 3% base erosion percentage threshold is met.
Key Analytical Point. The CSA and royalty arrangements that are the focus of the IRS's proposed IRC § 482 adjustments involve payments flowing from PBI to PPC — that is, inbound to the United States, not outbound. Accordingly, the core § 482 adjustments are unlikely to directly trigger additional BEAT liability for PPC. The BEAT is designed to address the erosion of the U.S. tax base through outbound deductible payments, not the understatement of inbound income.
C. Indirect BEAT Implications
Although the direct BEAT impact of the IRS's proposed § 482 adjustments is minimal, there are several indirect channels through which the adjustments could affect PPC's BEAT computation.
Impact on Modified Taxable Income. If the IRS's § 482 adjustments are sustained, the recharacterization of income from PBI to PPC would increase PPC's U.S. taxable income and, correspondingly, increase PPC's regular tax liability. Under the BEAT framework, a higher regular tax liability makes it less likely that the BEAT minimum tax will exceed the regular tax (since the BEAT applies only to the extent that the BEAT amount exceeds the regular tax). In this sense, the § 482 adjustments have an indirectly favorable effect on PPC's BEAT posture by raising the regular tax "floor" above which the BEAT would bite.
Cost-Sharing Payments from PPC to PBI. Under the CSA structure as described in Section III.A, cost-sharing payments flow from PBI to PPC. However, to the extent PPC makes any payments to PBI under the CSA — for example, if PPC reimburses PBI for intangible development costs incurred by PBI with respect to cost-shared intangibles developed by PBI — such payments could potentially be characterized as base erosion payments. PPC's position, based on a review of the CSA's payment flows, is that no material payments of this nature exist. PBI's role is primarily as a payor of cost-sharing contributions, not as a recipient of reimbursements from PPC for PBI-incurred development costs. This position should be confirmed with Crestfield & Associates.
Contract Manufacturing Arrangement. Penterra Manufacturing Ireland Limited ("PMI") is a wholly owned subsidiary of PBI that manufactures certain pharmaceutical products for PBI and PPC pursuant to a contract manufacturing arrangement at a cost-plus-8% markup. PMI is an Irish entity, and payments from PBI to PMI are between two Irish entities and do not directly involve PPC. However, if PPC makes any direct payments to PMI or other foreign affiliates for manufacturing services — for example, for contract manufacturing of products sold in the Americas — such payments could be base erosion payments by PPC. This issue should be examined in coordination with Crestfield & Associates (engagement partner: Martin Ogilvy, CPA) to confirm that PPC's direct payments to foreign affiliates for services are properly identified and quantified for BEAT computation purposes.
D. BEAT and the Correlative Offset
The $42.65 million correlative offset allowed by the IRS examination team to avoid double-counting between the CSA cost-sharing ratio adjustments and the royalty rate adjustments should be analyzed for any BEAT interaction. Specifically, the correlative offset reduces the net § 482 adjustment — and therefore the increase in PPC's taxable income — which could marginally reduce the favorable indirect BEAT effect described in Section VI.C above (i.e., the offset slightly reduces the increase in PPC's regular tax that would otherwise raise the BEAT floor).
However, given the direction of the core payment flows (inbound to the U.S.) and the absence of any direct base erosion payment component in the proposed adjustments, the BEAT impact of the correlative offset is expected to be minimal.
VII. FDII Regime (IRC § 250) — Potential Interaction
A. Overview. IRC § 250, enacted by TCJA § 14202, provides a deduction for "foreign-derived intangible income" ("FDII") that results in an effective U.S. tax rate of 13.125% on qualifying FDII (for taxable years beginning before January 1, 2026; 16.406% thereafter, when the deduction decreases from 37.5% to 21.875%). FDII is designed to incentivize U.S. corporations to retain intangible-income-generating activities in the United States by offering a preferential rate on income derived from serving foreign markets.
FDII is computed as the portion of a domestic corporation's "deemed intangible income" ("DII") that is attributable to foreign-derived income. DII is the excess of a corporation's "deduction eligible income" ("DEI") over a 10% deemed return on its QBAI. The foreign-derived portion is determined by the ratio of the corporation's "foreign-derived deduction eligible income" ("FDDEI") to its total DEI. FDDEI includes income from (i) the sale of property to foreign persons for foreign use and (ii) the provision of services to foreign persons or with respect to property located outside the United States.
B. Potential Interaction with § 482 Adjustments
If the IRS reallocates income from PBI to PPC under IRC § 482, some of that reallocated income could potentially qualify as FDII to the extent it is attributable to PPC's service of foreign markets. The logic underlying this argument is straightforward: the income that PBI was earning from Non-Americas sales was, by definition, income derived from serving foreign markets. If the IRS recharacterizes that income as properly belonging to PPC, PPC could argue that the recharacterized income constitutes FDDEI — income that PPC earned by providing intangible property (pharmaceutical IP) for foreign use.
However, the applicability of the FDII deduction to recharacterized § 482 income is subject to significant analytical complexity. The following issues must be addressed:
Related-Party Limitations. IRC § 250(b)(5)(B) provides specific rules for transactions with related parties. For sales of property to a related party, the property must be "for a foreign use" — that is, the property must ultimately be sold to an unrelated foreign person or used in connection with property that is sold to an unrelated foreign person, or the property must be used by the related party in the active conduct of a trade or business outside the United States. Royalty income received from a related CFC for the license of intangible property may qualify as FDDEI to the extent the related CFC uses the licensed intangible property in the active conduct of a trade or business outside the United States, provided the documentation requirements of Treas. Reg. § 1.250(b)-5 are satisfied.
Characterization of Recharacterized Income. The character of the recharacterized income for FDII purposes is unclear. If the IRS's adjustment takes the form of an increased royalty rate, the recharacterized income would be additional royalty income from PBI — which may qualify as FDDEI if PBI uses the licensed IP in the active conduct of its trade or business outside the United States. If the adjustment takes the form of an increased CSA cost-sharing ratio, the recharacterized income may be more properly characterized as additional cost-sharing payment income, the FDII treatment of which is less clear.
Computational Complexity. Even if a portion of the recharacterized income qualifies as FDDEI, the FDII deduction is computed based on the corporation's overall DEI, FDDEI, and QBAI. The addition of recharacterized income to PPC's DEI and FDDEI would require a full recomputation of PPC's FDII amount, which in turn depends on PPC's aggregate QBAI and total DEI for each year.
This is an area requiring further analysis, and we recommend that Whitmore Valuation Group be engaged to model the potential FDII benefit of recharacterized income under various adjustment scenarios. To the extent FDII treatment is available, it would partially offset the tax cost of any § 482 adjustment for TY 2018–2020 by reducing the effective rate on the recharacterized income from 21% to as low as 13.125%.
VIII. Transition-Year Issues: TY 2017
A. Pre-TCJA Rate and No GILTI/BEAT
TY 2017 occupies a unique position in the examination because it is subject to the pre-TCJA international tax regime in its entirety. The key features of the pre-TCJA regime as they bear on PPC's transfer pricing exposure are:
35% Corporate Rate. The federal corporate income tax rate applicable to TY 2017 is 35%, the highest rate in the examination period and 14 percentage points above the post-TCJA rate.
No GILTI. The GILTI regime under IRC § 951A is not in effect for TY 2017. PBI's income that is not "Subpart F income" under IRC §§ 951–964 (e.g., foreign base company sales income under IRC § 954(d) or foreign personal holding company income under IRC § 954(c)) is not currently taxable to PPC. To the extent PBI's pharmaceutical business income is derived from active business operations in Ireland and the Non-Americas Territory — as PPC's transfer pricing documentation and PBI's substance support — PBI's income is generally not Subpart F income and is subject to indefinite deferral until repatriated as a dividend.
No BEAT. The BEAT under IRC § 59A is not in effect for TY 2017.
No FDII. The FDII deduction under IRC § 250 is not available for TY 2017.
The absence of GILTI in TY 2017 is the most consequential difference for purposes of analyzing § 482 adjustment exposure. Because PBI's income was subject to deferral in TY 2017 (to the extent it was not Subpart F income), a § 482 adjustment that reallocates income from PBI to PPC for TY 2017 has no GILTI offset. PPC bears the full 35% rate on any reallocated income, without any mitigating reduction attributable to lower GILTI inclusions that PPC would otherwise have reported.
B. Comparative Exposure: TY 2017 vs. 2018–2020
The following table provides a comprehensive comparison of the effective tax cost per dollar of IRC § 482 adjustment across the examination years, incorporating the rate differential, the GILTI offset for TY 2018–2020, and the penalty exposure:
The differential is significant. TY 2017 adjustments are approximately 70% to 125% more costly on a per-dollar basis than TY 2018–2020 adjustments:
• Compared to the post-TCJA KDB scenario: $0.350 / $0.155 = 2.26x (i.e., TY 2017 is 126% more costly per dollar of adjustment).
• Compared to the post-TCJA standard rate scenario: $0.350 / $0.205 = 1.71x (i.e., TY 2017 is 71% more costly per dollar of adjustment).
• Including penalties, the differential is similar: $0.420 / $0.197 = 2.13x (KDB scenario) and $0.420 / $0.247 = 1.70x (standard rate scenario).
C. Transition Year Considerations
The TCJA transition tax under IRC § 965 — the mandatory repatriation of accumulated post-1986 deferred foreign earnings — may also interact with the IRS's proposed § 482 adjustments for TY 2017, creating a potentially beneficial secondary effect.
IRC § 965 applies to the last taxable year of a CFC beginning before January 1, 2018. For PBI, a calendar-year entity, this is PBI's fiscal year ending December 31, 2017. Under § 965, each U.S. shareholder of a CFC must include in income its pro rata share of the CFC's accumulated post-1986 deferred foreign income (the "§ 965(a) earnings amount"), measured as the greater of the CFC's accumulated post-1986 E&P as of November 2, 2017 or December 31, 2017.
If the IRS's § 482 adjustment for TY 2017 reduces PBI's income — which it does, because the adjustment reallocates income from PBI to PPC — then PBI's accumulated post-1986 E&P as of the measurement dates may be correspondingly reduced. A reduction in PBI's accumulated E&P would reduce PPC's § 965(a) earnings amount and, therefore, reduce PPC's transition tax liability under § 965.
The transition tax rate under § 965(c) is 15.5% on the portion of the § 965(a) earnings amount attributable to cash or cash-equivalent assets and 8% on the remainder. The potential reduction in PPC's § 965 liability from a conforming E&P reduction could partially offset the tax cost of the TY 2017 § 482 adjustment.
This beneficial interaction should be evaluated in detail, including: (i) the amount of PPC's § 965(a) earnings amount as originally reported; (ii) the portion attributable to PBI; (iii) the cash/non-cash split for purposes of the § 965(c) rate; and (iv) whether PPC elected to pay its § 965 liability in installments under § 965(h) and the implications of a retroactive reduction in the liability. This analysis should be coordinated with Crestfield & Associates, which prepared PPC's original § 965 computations.
IX. Impact on Settlement and Defense Strategy
A. Rate Differential in Settlement Calculations
Any settlement analysis must separately model the tax-dollar impact of adjustments for TY 2017 at the 35% rate and for TY 2018–2020 at the 21% rate. The GILTI offsets identified in Section V.C above must also be incorporated into the settlement model, as they materially affect the net tax cost of adjustments for the post-TCJA years.
The allocation of any global settlement adjustment across the four examination years is a critical variable. Because each dollar of TY 2017 adjustment carries approximately 70% to 125% more tax cost than a dollar of TY 2018–2020 adjustment (depending on PBI's Irish effective tax rate), PPC should seek, in any settlement negotiation, to allocate a disproportionate share of any aggregate concession to TY 2018–2020, where the per-dollar tax cost is lower. Conversely, PPC should seek to minimize the TY 2017 component of any settlement.
The settlement adjustment allocation across years should be modeled using a sensitivity analysis that varies the year-by-year allocation and computes the resulting aggregate tax cost under multiple scenarios. The defense team should prepare this analysis in advance of any settlement discussions, incorporating the rate differential, GILTI offsets at both the KDB and standard Irish rates, potential FDII benefits, and penalty exposure.
B. GILTI Offset as Defense Argument
The GILTI regime's partial offset to IRC § 482 adjustments may reduce the IRS's institutional incentive to pursue the full amount of the proposed adjustments for TY 2018–2020. From the government's perspective, the net revenue gain from a § 482 adjustment is not the headline 21% of the adjustment amount, but rather the net of the 21% incremental tax and the reduction in GILTI tax that would otherwise have been collected on PBI's income. At the KDB rate, this net revenue gain is only approximately $0.155 per dollar of adjustment, which is less than half the revenue gain that the same adjustment would produce for TY 2017 ($0.35 per dollar).
This economic reality may have persuasive value in Appeals negotiations. The IRS Office of Appeals considers the hazards of litigation and the expected government recovery in evaluating settlement proposals. By demonstrating that the government's net recovery from the TY 2018–2020 adjustments is substantially less than the nominal adjustment amount suggests, PPC may be able to negotiate a more favorable settlement posture.
Additionally, the GILTI offset argument may be useful in demonstrating that the IRS's proposed adjustments, if fully sustained, would produce a distorted result in which PPC's total U.S. tax liability (regular tax plus GILTI) actually decreases for PBI's operations while increasing for PPC's domestic operations — an outcome that arguably undermines the policy purpose of the § 482 adjustment, which is to ensure that the correct amount of income is attributed to U.S. activities.
C. BEAT Non-Applicability as Favorable Factor
As discussed in Section VI, the BEAT regime does not appear to create material additional exposure for PPC in connection with the IRS's proposed § 482 adjustments, because the core intercompany arrangements at issue involve inbound (not outbound) payments. This is a favorable factor for PPC's overall posture in the examination and in any settlement discussions.
The absence of BEAT exposure means that PPC does not face the "stacking" risk that some multinationals encounter in IRS examinations — i.e., the risk that § 482 adjustments could simultaneously trigger additional BEAT liability by increasing modified taxable income while decreasing base erosion tax benefits. PPC's payment flow structure — with cost-sharing payments and royalties flowing from PBI to PPC — avoids this risk entirely.
This favorable factor should be emphasized in any presentation to the IRS examination team or to Appeals, as it demonstrates that PPC's intercompany arrangements are structured in a manner that does not implicate the anti-base-erosion concerns that motivated the BEAT legislation.
X. Recommendations
Based on the foregoing analysis, we recommend the following actions:
1. TY 2017 Focus. Devote particular attention and defense resources to defending PPC's TY 2017 transfer pricing positions, given the 35% corporate tax rate applicable to that year and the absence of any GILTI offset to mitigate the tax cost of an adverse adjustment. The TY 2017 positions carry the highest per-dollar exposure of any examination year, and any concession on TY 2017 should be viewed as approximately twice as costly as a comparable concession on TY 2018–2020. The economic analyses being prepared by Whitmore Valuation Group should include a particularly robust defense of the arm's-length character of PPC's 2017 CSA cost-sharing ratios and legacy IP royalty rate.
2. GILTI Conforming Adjustments. Ensure that any settlement or agreed adjustment for TY 2018–2020 explicitly provides for corresponding reductions to PPC's GILTI inclusions on Forms 8992 and related schedules. The conforming GILTI adjustment is not automatic and must be affirmatively claimed by PPC. The settlement agreement or closing agreement should include specific language providing for the recomputation of PPC's GILTI inclusion amounts to reflect the reduced tested income of PBI resulting from the § 482 adjustment. Failure to secure this language could result in PPC bearing both the full § 482 tax and the unreduced GILTI tax — an impermissible double tax that the conforming adjustment mechanism is designed to prevent.
3. FDII Analysis. Commission further analysis from Whitmore Valuation Group on whether any portion of income recharacterized under § 482 could qualify as foreign-derived intangible income under IRC § 250, thereby benefiting from the reduced 13.125% effective rate. This analysis should model the FDII benefit under various recharacterization scenarios and should address the related-party limitations of IRC § 250(b)(5)(B) and the documentation requirements of the § 250 regulations.
4. § 965 Interaction. Analyze whether the IRS's proposed TY 2017 § 482 adjustment affects PBI's accumulated post-1986 earnings and profits for purposes of the § 965 transition tax. If the adjustment reduces PBI's E&P, PPC may be entitled to a conforming reduction in its § 965 inclusion amount and a corresponding refund of transition tax overpayment. This analysis should be coordinated with Crestfield & Associates, which prepared PPC's original § 965 computations and has access to the detailed E&P schedules and cash position data necessary for the calculation.
5. BEAT Monitoring. Continue to monitor PPC's base erosion percentage on an annual basis to confirm that PPC does not cross the 3% threshold that would make it an "applicable taxpayer" for BEAT purposes. This monitoring should be conducted in coordination with Crestfield & Associates (engagement partner: Martin Ogilvy, CPA) and should include a review of all intercompany payments from PPC to foreign affiliates, including management fees, service charges, and any cost-sharing payments flowing from PPC to PBI or other foreign entities. If PPC's base erosion percentage approaches the 3% threshold, additional BEAT planning and analysis may be warranted.
6. Settlement Modeling. Incorporate the rate differential, GILTI offsets, potential FDII benefits, § 965 interaction, and all other TCJA-related considerations into the sensitivity analysis and settlement range modeling being prepared for the defense. The settlement model should compute the aggregate tax cost of various adjustment scenarios, allocating adjustments across TY 2017–2020 in varying proportions, and should identify the allocation that minimizes PPC's total federal tax exposure for any given global settlement amount. This modeling should be completed prior to any substantive settlement discussions with the IRS examination team or Appeals.
XI. Conclusion
The Tax Cuts and Jobs Act significantly reduces Penterra Pharmaceuticals Corp.'s per-dollar transfer pricing exposure for TY 2018–2020 compared to TY 2017, operating through two principal mechanisms. First, the rate reduction from 35% to 21% directly reduces the federal income tax attributable to each dollar of IRC § 482 adjustment by 40%. Second, the GILTI regime's interaction with § 482 adjustments creates a partial offset: because any adjustment that reallocates income from PBI to PPC simultaneously reduces PPC's GILTI inclusion on PBI's excess intangible income, the net incremental tax cost of each dollar of adjustment is further reduced from $0.21 to approximately $0.155–$0.205 per dollar (depending on PBI's Irish effective tax rate under the Knowledge Development box and standard trading rate).
The BEAT regime does not create material additional exposure for PPC in connection with the current examination, given the inbound direction of the intercompany payment flows at issue (cost-sharing payments and royalties flowing from PBI to PPC). The FDII deduction under IRC § 250 may provide an additional partial offset to the tax cost of any § 482 adjustment, but this requires further analysis of the recharacterized income's eligibility for FDII treatment.
TY 2017 remains the most consequential examination year on a per-dollar basis, with no GILTI offset, no FDII benefit, and a 35% federal rate. The § 965 transition tax interaction presents a potential countervailing benefit that warrants further investigation.
These dynamics should be integrated into both the economic analysis being coordinated with Whitmore Valuation Group LLC and the defense strategy being developed under Leonard Cross's direction. The rate differential and GILTI offset, in particular, should inform the allocation of defense resources across examination years, the structure of any settlement proposal, and the hazards-of-litigation analysis presented to the IRS Office of Appeals.
This memorandum should be read in conjunction with:
• The preliminary assessment memorandum dated June 15, 2022;
• The defense strategy memorandum dated July 12, 2022; and
• The CSA regulatory analysis memorandum dated August 5, 2022.
This memorandum has been prepared for

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

MEMORANDUM

MATTER NO.: 1018-00009

Record

Parties

Dates

Amounts